Inhaltsverzeichnis Glofitamab Monotherapie (COLUMVI®)

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Number of centers/countries/geographical regions with <10, >=10 patients per arm

	Center				Country				Geographical region (3)			
Category	n (4)	% (5)	n of patients (6)	% of patients (7)	n (4)	% (5)	n of patients (6)	% of patients (7)	n (4)	% (5)	n of patients (6)	% of patients (7)
Overall	32	100	155	100	13	100	155	100	4	100	155	100
with <10 patients per arm (1)	30	93,8	114	73,5	9	69,2	47	30,3	1	25	6	3,9
with >=10 patients per arm (2)	2	6,3	41	26,5	4	30,8	108	69,7	3	75	149	96,1

(1) "<10 patients category" if at least one treatment arm has <10 patients. (2) ">=10 patients" category if all treatment arms have >=10 patients.
(3) Geographical regions: North America (Canada and USA), Australia/New Zealand, Asia (Taiwan), Europe (all other countries). (4) Number of centers/countries/geographical regions.
(5) % of centers/countries/geographical regions compared to overall number of centers/countries/geographical regions.
(6) Number of patients in the corresponding category (e.g. Number of patients in centers with <10 pts per arm).
(7) % of patients in the corresponding category compared to overall number of patients in the population (e.g. % of patients in centers with <10 patients per arm compared to overall number of patients in the population).
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_center.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_center_JUN24_ITT_D235.xls
26FEB2025 14:43

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Number of patients who died including primary reason

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)
Total number of deaths	103 (66.9%)
Primary cause of death	
n	103
Adverse event	12 (11.7%)
Progressive disease	68 (66.0%)
Other	23 (22.3%)

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_dd.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_dd_JUN24_SE_D235.xls
16JAN2025 13:30

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Disposition of Patients

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)
Ongoing Study	39 (25.2%)
Discontinued Study	116 (74.8%)
Reason for Study Discontinuation	
Adverse Event	1 (0.6%)
Death	103 (66.5%)
Lost To Follow-Up	4 (2.6%)
Other	1 (0.6%)
Protocol Deviation	1 (0.6%)
Withdrawal By Subject	6 (3.9%)
Not Started Treatment	1 (0.6%)
Active on Treatment	0
Completed Treatment	39 (25.2%)
Discontinued Treatment	110 (71.0%)
Reason for Treatment Discontinuation	
Adverse Event	12 (7.7%)
Death	11 (7.1%)
Lack Of Efficacy	3 (1.9%)
Other	2 (1.3%)
Physician Decision	9 (5.8%)
Progressive Disease	64 (41.3%)
Protocol Deviation	1 (0.6%)

Symptomatic Deterioration	3 (1.9%)
Withdrawal By Subject	5 (3.2%)
Not Started Initial Treatment	1 (0.6%)
Active on Initial Treatment	0
Completed Initial Treatment	44 (28.4%)
Discontinued Initial Treatment	110 (71.0%)
Reason for Initial Treatment Discontinuation	
Adverse Event	12 (7.7%)
Death	11 (7.1%)
Lack Of Efficacy	3 (1.9%)
Other	2 (1.3%)
Physician Decision	9 (5.8%)
Progressive Disease	64 (41.3%)
Protocol Deviation	1 (0.6%)
Symptomatic Deterioration	3 (1.9%)
Withdrawal By Subject	5 (3.2%)
Active on Retreatment	0
Completed Retreatment	0
Discontinued Retreatment	5 (3.2%)
Reason for Retreatment Discontinuation	
Adverse Event	1 (0.6%)
Death	1 (0.6%)
Progressive Disease	3 (1.9%)

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_ds.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_ds_JUN24_ITT_D235.xls
16JAN2025 13:28

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Disposition of Patients

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)
Ongoing Study	39 (25.3%)
Discontinued Study	115 (74.7%)
Reason for Study Discontinuation	
Adverse Event	1 (0.6%)
Death	103 (66.9%)
Lost To Follow-Up	4 (2.6%)
Protocol Deviation	1 (0.6%)
Withdrawal By Subject	6 (3.9%)
Active on Treatment	0
Completed Treatment	39 (25.3%)
Discontinued Treatment	110 (71.4%)
Reason for Treatment Discontinuation	
Adverse Event	12 (7.8%)
Death	11 (7.1%)
Lack Of Efficacy	3 (1.9%)
Other	2 (1.3%)
Physician Decision	9 (5.8%)
Progressive Disease	64 (41.6%)
Protocol Deviation	1 (0.6%)

Symptomatic Deterioration	3 (1.9%)
Withdrawal By Subject	5 (3.2%)
Active on Initial Treatment	0
Completed Initial Treatment	44 (28.6%)
Discontinued Initial Treatment	110 (71.4%)
Reason for Initial Treatment Discontinuation	
Adverse Event	12 (7.8%)
Death	11 (7.1%)
Lack Of Efficacy	3 (1.9%)
Other	2 (1.3%)
Physician Decision	9 (5.8%)
Progressive Disease	64 (41.6%)
Protocol Deviation	1 (0.6%)
Symptomatic Deterioration	3 (1.9%)
Withdrawal By Subject	5 (3.2%)
Active on Retreatment	0
Completed Retreatment	0
Discontinued Retreatment	5 (3.2%)
Reason for Retreatment Discontinuation	
Adverse Event	1 (0.6%)
Death	1 (0.6%)
Progressive Disease	3 (1.9%)

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_ds.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_ds_JUN24_SE_D23
16JAN2025 13:27

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Demographic and Baseline Characteristics

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)
Age (yr)	
n	155
Mean (SD)	63.1 (14.7)
Median	66
Min - Max	21 - 90
Age group (yr)	
n	155
<65	71 (45.8%)
>=65	84 (54.2%)
Sex	
n	155
Male	101 (65.2%)
Female	54 (34.8%)
Ethnicity	
n	155
Hispanic or Latino	9 (5.8%)
Not Hispanic or Latino	121 (78.1%)
Not Stated	21 (13.5%)
Unknown	4 (2.6%)
Country	
n	155
Australia	8 (5.2%)
Belgium	4 (2.6%)
Canada	2 (1.3%)

Czech Republic	4 (2.6%)
Denmark	9 (5.8%)
Spain	20 (12.9%)
Finland	3 (1.9%)
France	29 (18.7%)
Italy	41 (26.5%)
New Zealand	3 (1.9%)
Poland	8 (5.2%)
Taiwan	6 (3.9%)
United States	18 (11.6%)
Race	
n	155
Asian	7 (4.5%)
Black or African American	3 (1.9%)
White	119 (76.8%)
Unknown	26 (16.8%)
Weight (kg)	
n	153
Mean (SD)	75.37 (17.15)
Median	73,7
Min - Max	44.4 - 151.1
Height (cm)	
n	152
Mean (SD)	170.52 (10.13)
Median	171
Min - Max	141.0 - 193.0
Body Mass Index (kg/m2) at Baseline	
n	152
Mean (SD)	25.73 (5.02)
Median	24,81
Min - Max	17.6 - 45.1
ECOG Status at Baseline	
0	69 (44.5%)
1	84 (54.2%)
2	1 (0.6%)
Missing/Unknown	1 (0.6%)

Cancer Hist. Subtype II at Study Entry	
Diffuse Large B-Cell Lymphoma	110 (71.0%)
High Grade B Cell Lymphoma	10 (6.5%)
Primary Mediastinal B Cell Lymphoma	6 (3.9%)
Transformed Follicular Lymphoma	29 (18.7%)

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_dm.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_dm_JUN24_ITT_D235.xls
16JAN2025 13:23

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Demographic and Baseline Characteristics

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)
Age (yr)	
n	154
Mean (SD)	63.2 (14.6)
Median	66
Min - Max	21 - 90
Age group (yr)	
n	154
<65	70 (45.5%)
>=65	84 (54.5%)
Sex	
n	154
Male	100 (64.9%)
Female	54 (35.1%)
Ethnicity	
n	154
Hispanic or Latino	9 (5.8%)
Not Hispanic or Latino	120 (77.9%)
Not Stated	21 (13.6%)
Unknown	4 (2.6%)
Country	
n	154
Australia	8 (5.2%)
Belgium	4 (2.6%)

Canada	2 (1.3%)
Czech Republic	4 (2.6%)
Denmark	9 (5.8%)
Spain	19 (12.3%)
Finland	3 (1.9%)
France	29 (18.8%)
Italy	41 (26.6%)
New Zealand	3 (1.9%)
Poland	8 (5.2%)
Taiwan	6 (3.9%)
United States	18 (11.7%)
Race	
n	154
Asian	7 (4.5%)
Black or African American	3 (1.9%)
White	118 (76.6%)
Unknown	26 (16.9%)
Weight (kg)	
n	153
Mean (SD)	75.37 (17.15)
Median	73,7
Min - Max	44.4 - 151.1
Height (cm)	
n	152
Mean (SD)	170.52 (10.13)
Median	171
Min - Max	141.0 - 193.0
Body Mass Index (kg/m2) at Baseline	
n	152
Mean (SD)	25.73 (5.02)
Median	24,81
Min - Max	17.6 - 45.1
ECOG Status at Baseline	
0	69 (44.8%)
1	84 (54.5%)

2	1 (0.6%)
Cancer Hist. Subtype II at Study Entry	
Diffuse Large B-Cell Lymphoma	110 (71.4%)
High Grade B Cell Lymphoma	10 (6.5%)
Primary Mediastinal B Cell Lymphoma	6 (3.9%)
Transformed Follicular Lymphoma	28 (18.2%)

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_dm.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_dm_JUN24_SE_D235.xls
16JAN2025 13:22

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Summary of Baseline Disease Characteristics

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)
Ann Arbor Staging at Study Entry	
n	155
STAGE I	11 (7.1%)
STAGE II	24 (15.5%)
STAGE III	31 (20.0%)
STAGE IV	85 (54.8%)
UNKNOWN	4 (2.6%)
Risk factors for IPI (non-FL patients only)	
n	155
0	5 (3.2%)
1	25 (16.1%)
2	43 (27.7%)
3	56 (36.1%)
4	26 (16.8%)
Extranodal Disease	
n	155
No	60 (38.7%)
Yes	95 (61.3%)
Bulky Disease > 6cm	
n	154
No	90 (58.1%)
Yes	64 (41.3%)
Bulky Disease > 10cm	
n	154

No	135 (87.1%)
Yes	19 (12.3%)
Baseline Sum of Products of Diameters Value (mm2) - Investigator	
n	153
Mean (SD)	5385.29 (6242.16)
Median	3415
Min - Max	48.7 - 40152.0
Category Sum of Products of Diameters Value >=3000 (mm2) - Investigator	
n	153
Baseline SPD < 3000	71 (45.8%)
Baseline SPD >= 3000	82 (52.9%)
Category Sum of Products of Diameters Value >=10000 (mm2) - Investigator	
n	153
Baseline SPD < 10000	133 (85.8%)
Baseline SPD >= 10000	20 (12.9%)
Absence of circulating malignant cells	
n	35
No	5 (3.2%)
Yes	30 (19.4%)
Cancer Histological Subtype	
n	155
DLBCL	110 (71.0%)
HGBCL	10 (6.5%)
PMBCL	6 (3.9%)
trFL	29 (18.7%)
Cancer Grouped Histology	
n	155
aNHL	155 (100%)

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_mh_char.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_mh_char_JUN24_ITT_D235.xls
16JAN2025 13:26

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Summary of Baseline Disease Characteristics

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)
Ann Arbor Staging at Study Entry	
n	154
STAGE I	11 (7.1%)
STAGE II	24 (15.6%)
STAGE III	31 (20.1%)
STAGE IV	85 (55.2%)
UNKNOWN	3 (1.9%)
Risk factors for IPI (non-FL patients only)	
n	154
0	4 (2.6%)
1	25 (16.2%)
2	43 (27.9%)
3	56 (36.4%)
4	26 (16.9%)
Extranodal Disease	
n	154
No	59 (38.3%)
Yes	95 (61.7%)
Bulky Disease > 6cm	
n	154
No	90 (58.4%)
Yes	64 (41.6%)
Bulky Disease > 10cm	
n	154

No	135 (87.7%)
Yes	19 (12.3%)
Baseline Sum of Products of Diameters Value (mm2) - Investigator	
n	153
Mean (SD)	5385.29 (6242.16)
Median	3415
Min - Max	48.7 - 40152.0
Category Sum of Products of Diameters Value >=3000 (mm2) - Investigator	
n	153
Baseline SPD < 3000	71 (46.1%)
Baseline SPD >= 3000	82 (53.2%)
Category Sum of Products of Diameters Value >=10000 (mm2) - Investigator	
n	153
Baseline SPD < 10000	133 (86.4%)
Baseline SPD >= 10000	20 (13.0%)
Absence of circulating malignant cells	
n	35
No	5 (3.2%)
Yes	30 (19.5%)
Cancer Histological Subtype	
n	154
DLBCL	110 (71.4%)
HGBCL	10 (6.5%)
PMBCL	6 (3.9%)
trFL	28 (18.2%)
Cancer Grouped Histology	
n	154
aNHL	154 (100%)

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_mh_char.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_mh_char_JUN24_SE_D235.xls
16JAN2025 13:25

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Summary of Previous Cancer Therapies

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)
Prior Cancer-related Surgery	54 (34.8%)
Prior Radiotherapy	49 (31.6%)
Prior Cancer Therapy	155 (100%)
Chemotherapy	155 (100%)
Anti-CD20 Monoclonal Antibody	155 (100%)
Non Anti-CD20 Monoclonal Antibody	25 (16.1%)
Conditioning Regimen For Stem Cell Transplant	58 (37.4%)
Signaling Pathway Inhibitor	17 (11.0%)
Immunotherapy Non Stem Cell Transplant	14 (9.0%)
PI3 KINASE INHIBITOR	3 (1.9%)
CAR-T CELL THERAPY	52 (33.5%)
Anthracycline	152 (98.1%)
ALKYLATOR	155 (100%)
IMMUNOMODULATORY IMIDE DRUG	22 (14.2%)
Autologous Stem Cell Transplant	29 (18.7%)
Other	36 (23.2%)
Number of Prior Lines of Cancer Therapy per Subject	
n	155
Mean (SD)	3.1 (1.2)
Median	3
Min - Max	2 - 7

Prior Lines of Cancer Therapy per Subject (Cat)	
2	61 (39.4%)
3	48 (31.0%)
>3	46 (29.7%)
Numbers of Prior Lines of Cancer Therapy (N)	
2	61 (39.4%)
3	48 (31.0%)
4	28 (18.1%)
5	10 (6.5%)
6	5 (3.2%)
7	3 (1.9%)
Category Time from Last Prior Therapy to First Study Treatment (0-3 vs. 3+)(Months)	
<3	79 (51.0%)
>=3	71 (45.8%)
Category Time from Last Prior CD20 Therapy to First Study Treatment (0-3 vs. 3+)(Months)	
<=3	51 (32.9%)
>3	99 (63.9%)
Time from Last Prior Therapy to First Study Treatment (Months)	
n	150
Mean (SD)	6.71 (15.33)
Median	2,7
Min - Max	0.3 - 147.3
Time from Last Anti-CD20 Therapy to First Study Treatment (Months)	
n	150
Mean (SD)	12.21 (23.50)
Median	4,75
Min - Max	0.9 - 198.9

Category Time from Last Prior Therapy, or Last Prior CD20 Therapy, is not available where Medication End date is missing the month or First Study Treatment is missing.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_cm_prior.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_cm_prior_JUN24_ITT_D235.xls
31MAR2025 12:25

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Summary of Previous Cancer Therapies

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)
Prior Cancer-related Surgery	54 (35.1%)
Prior Radiotherapy	49 (31.8%)
Prior Cancer Therapy	154 (100%)
Chemotherapy	154 (100%)
Anti-CD20 Monoclonal Antibody	154 (100%)
Non Anti-CD20 Monoclonal Antibody	25 (16.2%)
Conditioning Regimen For Stem Cell Transplant	58 (37.7%)
Signaling Pathway Inhibitor	17 (11.0%)
Immunotherapy Non Stem Cell Transplant	14 (9.1%)
PI3 KINASE INHIBITOR	3 (1.9%)
CAR-T CELL THERAPY	51 (33.1%)
Anthracycline	151 (98.1%)
ALKYLATOR	154 (100%)
IMMUNOMODULATORY IMIDE DRUG	22 (14.3%)
Autologous Stem Cell Transplant	29 (18.8%)
Other	35 (22.7%)
Number of Prior Lines of Cancer Therapy per Subject	
n	154
Mean (SD)	3.1 (1.2)
Median	3
Min - Max	2 - 7

Prior Lines of Cancer Therapy per Subject (Cat)	
2	61 (39.6%)
3	47 (30.5%)
>3	46 (29.9%)
Numbers of Prior Lines of Cancer Therapy (N)	
2	61 (39.6%)
3	47 (30.5%)
4	28 (18.2%)
5	10 (6.5%)
6	5 (3.2%)
7	3 (1.9%)
Category Time from Last Prior Therapy to First Study Treatment (0-3 vs. 3+)(Months)	
<3	79 (51.3%)
>=3	71 (46.1%)
Category Time from Last Prior CD20 Therapy to First Study Treatment (0-3 vs. 3+)(Months)	
<=3	51 (33.1%)
>3	99 (64.3%)
Time from Last Prior Therapy to First Study Treatment (Months)	
n	150
Mean (SD)	6.71 (15.33)
Median	2,7
Min - Max	0.3 - 147.3
Time from Last Anti-CD20 Therapy to First Study Treatment (Months)	
n	150
Mean (SD)	12.21 (23.50)
Median	4,75
Min - Max	0.9 - 198.9

Category Time from Last Prior Therapy, or Last Prior CD20 Therapy, is not available where Medication End date is missing the month or First Study Treatment is missing.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_cm_prior.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_cm_prior_JUN24_SE_D235.xls
31MAR2025 12:21

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Summary of Refractory and Relapse Status to Prior Lines of Therapy

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)
Relapse or Refractory to Any Prior Therapy	
n	155
Refractory	139 (89.7%)
Relapse (No Refractory)	16 (10.3%)
Relapse or Refractory to Last Line of Prior Therapy	
n	155
Refractory	130 (83.9%)
Relapse	25 (16.1%)
Relapse or Refractory to First Line of Prior Therapy	
n	155
Refractory	91 (58.7%)
Relapse	64 (41.3%)
Relapse or Refractory to Any Prior Anti-CD20 Therapy	
n	155
Refractory	129 (83.2%)
Relapse (No Refractory)	26 (16.8%)
Relapse or Refractory to Any Prior Alkylator Therapy	
n	155
Refractory	128 (82.6%)
Relapse (No Refractory)	27 (17.4%)

Relapse or Refractory to Any Prior CAR-T Therapy	
n	155
Not Applicable	103 (66.5%)
Refractory	46 (29.7%)
Relapse (No Refractory)	6 (3.9%)
Relapse or Refractory to Any Prior Pi3K Therapy	
n	155
Not Applicable	152 (98.1%)
Refractory	2 (1.3%)
Relapse (No Refractory)	1 (0.6%)
Relapse or Refractory to Any Prior Autologous Stem Cell Transplant Therapy	
n	155
Not Applicable	126 (81.3%)
Refractory	12 (7.7%)
Relapse (No Refractory)	17 (11.0%)
Relapse or Refractory to Any Prior Conditioning Regiment to Stem Cell Transplant Therapy	
n	155
Not Applicable	97 (62.6%)
Refractory	29 (18.7%)
Relapse (No Refractory)	29 (18.7%)
Progress or Relapse within 24 months after 1L Treatment Start	
n	155
No	32 (20.6%)
Yes	123 (79.4%)
Double Refractory to Both Anti-CD20 and Alkylating Agent Prior Therapies	
n	155
No	30 (19.4%)
Yes	125 (80.6%)

Primary Refractory	
n	155
No	119 (76.8%)
Yes	36 (23.2%)

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_cm_rrstat.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_cm_rrstat_JUN24_ITT_D235.xls
17JAN2025 15:31

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Duration of follow-up

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)
Median follow-up time (months)	
n	155
Mean	17,99
Median	9,49
Min - Max	0.1 - 52.3

Median follow-up time is time from patient randomization to study discontinuation date, death date or CCOD, whichever is the earliest.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_fut.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_fut_JUN24_ITT_D235.xls
16JAN2025 13:37

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Duration of follow-up

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)
Median follow-up time (months)	
n	154
Mean	6,51
Median	5,68
Min - Max	0.0 - 29.2

Median follow-up time is time from first dose to end of 90 day safety follow up period or earliest of CCOD, NALT, study discontinuation or start of a re-treatment.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/oth_fut.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/oth_fut_JUN24_SE_D235.xls
16JAN2025 13:36

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: Overall Survival
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	155	100,0	103	66,5	52	33,5	5,13	3,22	6,74	12,55	7,89	17,77

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D235_OS.xls
24JAN2025 0:04

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: Overall Survival
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																			
Glofitamab Cohorts D2 (Sub 2), D3, D5	155	121	103	78	73	68	59	56	52	50	45	38	29	26	20	13	3	1	NE
Patients censored																			
Glofitamab Cohorts D2 (Sub 2), D3, D5	0	8	9	10	10	11	11	12	12	13	14	21	28	30	35	41	49	51	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D235_OS.pdf
24JAN2025 0:05

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: Overall Survival
MODEL: --
STUDY: NP30179
Time to event landmark analysis

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)
Patients included in analysis (%)	155 (100%)
Patients with event (%)	103 (66.5%)
Patients without event (%)	52 (33.5%)
Time to event (months)	
Median	12,6
95% CI	(7.9, 17.8)
25% and 75%-ile	5.1 - 46.0
Range	0.1 - 52.3*
Time point analysis (Unstratified)	
12 Months	
Patients remaining at risk	73
Event free proportion (%)	50,83
95% CI	(42.70, 58.95)
24 Months	
Patients remaining at risk	52
Event free proportion (%)	37,37
95% CI	(29.45, 45.28)
36 Months	
Patients remaining at risk	29

Event free proportion (%)	31,85
95% CI	(24.10, 39.60)
48 Months	
Patients remaining at risk	3
Event free proportion (%)	21,07
95% CI	(10.96, 31.18)

* Censored values.
Summaries of time to event (median, percentiles) are based on Kaplan Meier estimates.
95% CI for median was computed using the method of Brookmeyer and Crowley.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_lma.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_lma_JUN24_ITT_D235_OS.xls
24JAN2025 0:06

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: IRC Assessed Progression Free Survival
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	155	100,0	111	71,6	44	28,4	1,41	1,28	2,50	4,86	3,45	7,82

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D235_IRCPFS.xls
24JAN2025 0:01

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: IRC Assessed Progression Free Survival
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																			
Glofitamab Cohorts D2 (Sub 2), D3, D5	155	92	60	51	46	41	38	35	32	29	25	18	17	14	10	3	3	1	NE
Patients censored																			
Glofitamab Cohorts D2 (Sub 2), D3, D5	0	13	18	18	20	21	21	21	21	22	23	28	28	30	34	41	41	43	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D235_IRCPFS.pdf
24JAN2025 0:02

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: IRC Assessed Progression Free Survival
MODEL: --
STUDY: NP30179
Time to event landmark analysis

	Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)
Patients included in analysis (%)	155 (100%)
Patients with event (%)	111 (71.6%)
Patients without event (%)	44 (28.4%)
Time to event (months)	
Median	4,9
95% CI	(3.4, 7.8)
25% and 75%-ile	1.4 - 26.1
Range	0.0* - 52.3*
Time point analysis (Unstratified)	
12 Months	
Patients remaining at risk	46
Event free proportion (%)	36,68
95% CI	(28.59, 44.77)
24 Months	
Patients remaining at risk	32
Event free proportion (%)	26,09
95% CI	(18.57, 33.62)
36 Months	
Patients remaining at risk	17

Event free proportion (%)	18,75
95% CI	(11.78, 25.72)
48 Months	
Patients remaining at risk	3
Event free proportion (%)	17,58
95% CI	(10.68, 24.48)

* Censored values.
Summaries of time to event (median, percentiles) are based on Kaplan Meier estimates.
95% CI for median was computed using the method of Brookmeyer and Crowley.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_lma.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_lma_JUN24_ITT_D235_IRCPFS.xls
24JAN2025 0:03

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: IRC Assessed BOR
MODEL: --
STUDY: NP30179
Dichotomous analysis (efficacy)

			Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)					
			Patients		Patients with Event			
Name	Parameter	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	CR	n/a	155	100,0	62	40,0	32,6	47,9
	PR	n/a	155	100,0	18	11,6	7,5	17,6
	SD	n/a	155	100,0	21	13,5	9,0	19,8
	PD	n/a	155	100,0	42	27,1	20,7	34,6
	NE	n/a	155	100,0	0	0,0	0,0	2,4
	Missing or Not Done	n/a	155	100,0	12	7,7	4,5	13,0

Note: All patients without response data are included in the Not Done/Missing category.
95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_resp_new.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_resp_new_JUN24_ITT_D235_IRC.xls
29JAN2025 17:28

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: Duration of IRC Assessed Complete Response
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=155)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	62	40,0	29	46,8	33	53,2	14,42	6,54	22,01	29,80	21,98	NE

Only patients with IRC-assessed Complete Response are included in the analysis.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D235_IRCCR.xls
29JAN2025 17:33

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: Duration of IRC Assessed Complete Response
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																			
Glofitamab Cohorts D2 (Sub 2), D3, D5	62	51	46	40	39	38	36	33	28	25	21	16	14	10	6	3	2	NE	NE
Patients censored																			
Glofitamab Cohorts D2 (Sub 2), D3, D5	0	8	8	10	10	10	10	10	11	12	14	18	20	23	27	30	31	NE	NE

Only patients with IRC-assessed Complete Response are included in the analysis.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D235_IRCCR.pdf
29JAN2025 17:32

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	49	33,1	99	66,9	1,45	1,18	5,88	23,00	14,78	36,83

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30AP.xls
24MAR2025 21:47

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	59	37	31	29	24	23	21	19	14	14	11	10	7	5	3	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	55	74	79	80	84	84	84	85	86	86	89	90	92	94	96	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30AP.pdf
24MAR2025 22:01

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	48	32,4	100	67,6	0,89	0,49	2,86	26,48	4,47	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30CO.xls
24MAR2025 21:45

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	51	28	23	21	19	17	16	16	14	14	9	7	6	3	2	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	59	77	81	81	83	85	86	86	87	87	92	93	94	97	98	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30CO.pdf
24MAR2025 21:59

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	44	29,7	104	70,3	3,52	0,76	15,01	23,26	15,01	35,98

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30DI.xls
24MAR2025 21:44

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	64	36	29	28	24	18	18	17	13	12	8	7	6	4	3	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	57	81	86	87	90	91	91	91	94	94	97	97	98	100	101	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30DI.pdf
24MAR2025 21:58

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	47	31,8	101	68,2	2,00	1,41	4,86	18,53	7,79	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30DY.xls
24MAR2025 21:43

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	60	32	24	22	19	19	16	15	13	12	8	7	5	5	2	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	55	79	83	84	87	87	87	88	90	90	93	94	96	96	99	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30DY.pdf
24MAR2025 21:58

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	80	54,1	68	45,9	0,66	0,30	0,72	1,45	1,02	3,45

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30FA.xls
24MAR2025 21:56

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	36	23	17	15	13	12	10	10	9	9	6	5	3	2	1	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	44	55	57	57	59	59	59	59	60	60	62	63	65	66	67	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30FA.pdf
24MAR2025 22:10

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	48	32,4	100	67,6	1,64	1,35	4,14	20,01	8,28	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30NV.xls
24MAR2025 21:43

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	60	31	28	26	21	20	17	15	12	12	9	9	6	4	3	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	54	79	80	81	85	85	86	87	89	89	92	92	94	96	97	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30NV.pdf
24MAR2025 21:57

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	71	48,0	77	52,0	0,69	0,30	0,76	2,79	1,64	8,28

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30PA.xls
24MAR2025 21:49

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	37	21	17	15	11	11	10	9	7	7	5	4	1	1	1	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	51	63	65	66	69	69	69	69	70	70	72	73	76	76	76	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30PA.pdf
24MAR2025 22:03

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Insomnia (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	58	39,2	90	60,8	0,76	0,72	1,91	5,78	2,79	24,21

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30SL.xls
24MAR2025 21:55

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Insomnia (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	46	25	23	22	17	17	13	13	10	10	8	8	6	5	4	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	54	70	71	72	76	76	78	78	80	80	82	82	84	85	86	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30SL.pdf
24MAR2025 22:09

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	19,08	28,80
Cycle 1 Day 8	n/a	139	94,6	131	94,2	17,05	27,54
Cycle 2 Day 1	n/a	122	83,0	113	92,6	17,40	28,90
Cycle 3 Day 1	n/a	104	70,7	94	90,4	12,77	22,46
Cycle 5 Day 1	n/a	80	54,4	73	91,3	8,22	16,46
Cycle 7 Day 1	n/a	57	38,8	53	93,0	8,81	20,83
Cycle 9 Day 1	n/a	43	29,3	21	48,8	7,94	14,55
Cycle 12 Day 1	n/a	41	27,9	23	56,1	8,70	14,97
Treatment Completion/ET Visit	n/a	129	87,8	84	65,1	17,06	22,85
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	5,56	12,69
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	10,71	22,32
Follow up till Progression - 9 months	n/a	35	23,8	22	62,9	9,09	23,42
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	5,56	16,05
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	11,59	21,58
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	12,50	21,56
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	2,90	9,60
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	1,52	7,11
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	3,70	10,78
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	9,52	20,37
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	2,78	9,62
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	3,33	10,54
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	0,00	0,00
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	0,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	0,00	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30AP.xls
18NOV2024 16:07

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Appetite Loss
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30AP.pdf
29JAN2025 17:33

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	17,47	27,52
Cycle 1 Day 8	n/a	139	94,6	130	93,5	19,74	27,75
Cycle 2 Day 1	n/a	122	83,0	113	92,6	18,88	28,13
Cycle 3 Day 1	n/a	104	70,7	94	90,4	15,60	24,78
Cycle 5 Day 1	n/a	80	54,4	74	92,5	17,12	28,80
Cycle 7 Day 1	n/a	57	38,8	54	94,7	12,35	22,71
Cycle 9 Day 1	n/a	43	29,3	21	48,8	9,52	21,46
Cycle 12 Day 1	n/a	41	27,9	23	56,1	14,49	26,26
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	17,05	27,89
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	11,11	18,82
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	7,14	21,00
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	5,80	16,37
Follow up till Progression - 12 months	n/a	31	21,1	23	74,2	10,14	18,63
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	7,25	14,06
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	6,94	16,97
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	8,70	20,64
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	3,03	9,81
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	7,41	14,26
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	4,76	12,10
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	2,78	9,62
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	3,33	10,54
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	6,67	14,91
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	0,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	0,00	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30CO.xls
18NOV2024 16:06

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Constipation
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30CO.pdf
29JAN2025 17:31

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	8,97	18,94
Cycle 1 Day 8	n/a	139	94,6	131	94,2	10,18	21,84
Cycle 2 Day 1	n/a	122	83,0	114	93,4	8,19	18,58
Cycle 3 Day 1	n/a	104	70,7	94	90,4	8,51	20,70
Cycle 5 Day 1	n/a	80	54,4	73	91,3	10,50	22,82
Cycle 7 Day 1	n/a	57	38,8	54	94,7	9,26	21,88
Cycle 9 Day 1	n/a	43	29,3	21	48,8	6,35	13,41
Cycle 12 Day 1	n/a	41	27,9	23	56,1	8,70	18,03
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	7,75	16,71
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	5,56	16,05
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	9,52	21,96
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	10,14	15,68
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	15,28	25,97
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	7,25	14,06
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	8,33	14,74
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	10,14	23,43
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	6,06	22,15
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	14,81	26,13
Follow up till Progression - 30 months	n/a	16	10,9	15	93,8	22,22	34,88
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	13,89	30,01
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	16,67	32,39
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	20,00	44,72
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	0,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	0,00	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30DI.xls
18NOV2024 16:05

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Diarrhoea
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30DI.pdf
29JAN2025 17:30

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	144	98,0	20,60	25,85
Cycle 1 Day 8	n/a	139	94,6	130	93,5	16,92	24,29
Cycle 2 Day 1	n/a	122	83,0	114	93,4	16,67	23,15
Cycle 3 Day 1	n/a	104	70,7	94	90,4	16,31	23,82
Cycle 5 Day 1	n/a	80	54,4	74	92,5	15,32	22,87
Cycle 7 Day 1	n/a	57	38,8	54	94,7	16,05	19,14
Cycle 9 Day 1	n/a	43	29,3	21	48,8	19,05	19,92
Cycle 12 Day 1	n/a	41	27,9	23	56,1	15,94	22,18
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	18,99	25,84
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	18,06	16,97
Follow up till Progression - 6 months	n/a	37	25,2	27	73,0	13,58	23,13
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	15,94	29,93
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	13,89	23,91
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	14,49	22,08
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	13,89	19,45
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	17,39	19,77
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	10,61	21,54
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	11,11	16,17
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	9,52	15,63
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	8,33	15,08
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	13,33	17,21
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	20,00	18,26
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	0,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	0,00	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30DY.xls
18NOV2024 16:05

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Dyspnoea
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30DY.pdf
29JAN2025 17:29

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	39,39	26,10
Cycle 1 Day 8	n/a	139	94,6	132	95,0	37,08	27,24
Cycle 2 Day 1	n/a	122	83,0	114	93,4	35,48	24,33
Cycle 3 Day 1	n/a	104	70,7	94	90,4	33,04	22,79
Cycle 5 Day 1	n/a	80	54,4	74	92,5	30,63	21,84
Cycle 7 Day 1	n/a	57	38,8	53	93,0	25,16	20,80
Cycle 9 Day 1	n/a	43	29,3	21	48,8	22,75	21,79
Cycle 12 Day 1	n/a	41	27,9	23	56,1	27,54	25,92
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	34,82	24,39
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	20,37	13,77
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	23,81	22,57
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	25,60	28,71
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	24,07	24,88
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	24,15	27,96
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	29,17	23,58
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	19,81	23,44
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	16,67	22,42
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	24,07	20,61
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	30,16	21,54
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	27,78	28,62
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	25,56	20,32
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	26,67	12,67
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	33,33	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	33,33	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30FA.xls
18NOV2024 16:15

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Fatigue
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30FA.pdf
29JAN2025 17:44

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	4,60	13,53
Cycle 1 Day 8	n/a	139	94,6	132	95,0	6,44	17,43
Cycle 2 Day 1	n/a	122	83,0	114	93,4	4,39	9,68
Cycle 3 Day 1	n/a	104	70,7	94	90,4	4,61	11,82
Cycle 5 Day 1	n/a	80	54,4	74	92,5	3,15	9,82
Cycle 7 Day 1	n/a	57	38,8	54	94,7	2,16	7,27
Cycle 9 Day 1	n/a	43	29,3	21	48,8	3,17	8,53
Cycle 12 Day 1	n/a	41	27,9	23	56,1	4,35	11,48
Treatment Completion/ET Visit	n/a	129	87,8	85	65,9	6,08	15,18
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	2,78	8,03
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	4,17	10,76
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	2,17	5,74
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	1,39	4,71
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	4,35	10,32
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	5,56	14,47
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	2,17	7,63
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	2,27	7,79
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	1,85	5,39
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	5,95	12,42
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	0,00	0,00
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	0,00	0,00
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	0,00	0,00
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	0,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	0,00	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30NV.xls
18NOV2024 16:04

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Nausea/Vomiting
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30NV.pdf
29JAN2025 17:28

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	31,95	28,23
Cycle 1 Day 8	n/a	139	94,6	132	95,0	27,40	26,30
Cycle 2 Day 1	n/a	122	83,0	114	93,4	23,10	26,93
Cycle 3 Day 1	n/a	104	70,7	94	90,4	19,50	24,64
Cycle 5 Day 1	n/a	80	54,4	74	92,5	19,59	22,30
Cycle 7 Day 1	n/a	57	38,8	52	91,2	16,67	20,61
Cycle 9 Day 1	n/a	43	29,3	21	48,8	16,67	25,82
Cycle 12 Day 1	n/a	41	27,9	23	56,1	17,39	27,74
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	27,71	29,44
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	15,97	18,70
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	18,45	19,43
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	13,04	21,88
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	18,75	25,69
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	25,36	25,56
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	25,00	29,90
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	16,67	26,11
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	12,88	21,16
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	20,37	21,81
Follow up till Progression - 30 months	n/a	16	10,9	15	93,8	21,11	24,77
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	20,83	27,64
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	16,67	23,57
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	10,00	14,91
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	33,33	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	16,67	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30PA.xls
18NOV2024 16:09

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Pain
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30PA.pdf
29JAN2025 17:36

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Insomnia
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	144	98,0	31,71	29,32
Cycle 1 Day 8	n/a	139	94,6	132	95,0	30,56	27,64
Cycle 2 Day 1	n/a	122	83,0	113	92,6	28,61	29,16
Cycle 3 Day 1	n/a	104	70,7	93	89,4	24,37	28,72
Cycle 5 Day 1	n/a	80	54,4	74	92,5	28,38	28,50
Cycle 7 Day 1	n/a	57	38,8	53	93,0	25,16	26,07
Cycle 9 Day 1	n/a	43	29,3	21	48,8	25,40	27,70
Cycle 12 Day 1	n/a	41	27,9	23	56,1	26,09	28,35
Treatment Completion/ET Visit	n/a	129	87,8	84	65,1	27,78	27,30
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	25,00	22,52
Follow up till Progression - 6 months	n/a	37	25,2	27	73,0	12,35	18,83
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	13,04	19,43
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	18,06	21,93
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	21,74	25,84
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	26,39	27,77
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	23,19	30,87
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	16,67	28,64
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	25,93	29,27
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	21,43	30,96
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	19,44	33,21
Follow up till Progression - 36 months	n/a	10	6,8	9	90,0	14,81	33,79
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	26,67	43,46
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	0,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	0,00	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30SL.xls
18NOV2024 16:14

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Insomnia
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30SL.pdf
29JAN2025 17:43

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	66	44,6	82	55,4	1,02	0,72	1,45	5,78	2,83	8,51

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30CF.xls
24MAR2025 21:52

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	52	26	18	16	13	13	12	12	8	8	5	4	2	NE	NE	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	47	68	70	71	74	74	74	74	75	75	77	78	80	NE	NE	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30CF.pdf
24MAR2025 22:06

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	47	31,8	101	68,2	2,79	1,38	5,09	19,42	5,65	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30EF.xls
24MAR2025 21:51

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	63	35	30	27	24	24	19	19	16	15	12	10	7	4	1	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	55	74	79	80	83	83	84	84	87	87	90	92	95	97	100	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30EF.pdf
24MAR2025 22:05

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	67	45,3	81	54,7	0,76	0,72	1,45	3,55	2,79	8,51

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30PF.xls
24MAR2025 21:48

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	49	25	20	19	15	14	13	12	11	11	9	8	6	4	3	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	50	64	65	66	69	70	70	70	71	71	73	74	76	77	78	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30PF.pdf
24MAR2025 22:02

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	66	44,6	82	55,4	0,72	0,33	0,76	4,93	1,64	18,23

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30QL.xls
24MAR2025 21:46

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	45	27	22	20	15	15	12	11	10	10	9	8	4	3	2	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	51	63	67	68	72	72	72	72	73	73	74	75	78	79	80	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30QL.pdf
24MAR2025 22:00

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	79	53,4	69	46,6	0,43	0,26	0,72	2,30	1,02	4,17

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30RF.xls
24MAR2025 21:51

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	38	17	14	13	12	10	7	7	6	5	4	4	4	3	2	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	49	62	63	64	64	64	64	64	64	64	65	65	65	66	67	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30RF.pdf
24MAR2025 22:04

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	71	48,0	77	52,0	0,72	0,30	1,02	2,79	1,41	11,76

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M10C30SF.xls
24MAR2025 21:53

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning (MID 10, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	44	23	21	20	19	19	18	16	13	13	9	7	4	2	2	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	44	60	62	62	63	63	63	63	66	66	70	72	73	75	75	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M10C30SF.pdf
24MAR2025 22:07

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	84,71	22,09
Cycle 1 Day 8	n/a	139	94,6	132	95,0	88,26	17,80
Cycle 2 Day 1	n/a	122	83,0	114	93,4	87,13	19,21
Cycle 3 Day 1	n/a	104	70,7	94	90,4	89,01	15,56
Cycle 5 Day 1	n/a	80	54,4	73	91,3	87,44	15,41
Cycle 7 Day 1	n/a	57	38,8	54	94,7	86,42	15,89
Cycle 9 Day 1	n/a	43	29,3	21	48,8	87,30	19,65
Cycle 12 Day 1	n/a	41	27,9	23	56,1	81,16	23,19
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	84,30	18,32
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	86,11	16,79
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	83,93	17,85
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	82,61	22,74
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	83,33	22,52
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	82,61	22,18
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	83,33	17,72
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	84,06	21,60
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	85,61	19,45
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	79,63	20,26
Follow up till Progression - 30 months	n/a	16	10,9	15	93,8	76,67	23,40
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	77,78	21,71
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	85,00	22,84
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	80,00	18,26
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	50,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	66,67	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30CF.xls
18NOV2024 16:12

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Cognitive Functioning
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30CF.pdf
29JAN2025 17:40

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	74,89	21,40
Cycle 1 Day 8	n/a	139	94,6	132	95,0	78,96	19,81
Cycle 2 Day 1	n/a	122	83,0	114	93,4	79,63	20,81
Cycle 3 Day 1	n/a	104	70,7	93	89,4	80,11	20,78
Cycle 5 Day 1	n/a	80	54,4	73	91,3	81,32	18,35
Cycle 7 Day 1	n/a	57	38,8	54	94,7	80,56	21,96
Cycle 9 Day 1	n/a	43	29,3	21	48,8	83,73	19,80
Cycle 12 Day 1	n/a	41	27,9	23	56,1	78,14	25,16
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	77,39	20,51
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	83,68	16,39
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	80,95	17,98
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	81,88	23,12
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	79,86	26,57
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	81,52	22,88
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	77,31	22,52
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	80,68	25,55
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	82,58	23,28
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	76,85	21,87
Follow up till Progression - 30 months	n/a	16	10,9	15	93,8	80,37	20,96
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	79,17	29,84
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	85,83	13,06
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	78,33	15,14
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	75,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	91,67	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30EF.xls
18NOV2024 16:11

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Emotional Functioning
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30EF.pdf
29JAN2025 17:39

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	75,26	22,52
Cycle 1 Day 8	n/a	139	94,6	132	95,0	75,98	22,02
Cycle 2 Day 1	n/a	122	83,0	114	93,4	77,73	19,55
Cycle 3 Day 1	n/a	104	70,7	94	90,4	79,49	19,20
Cycle 5 Day 1	n/a	80	54,4	74	92,5	82,93	16,73
Cycle 7 Day 1	n/a	57	38,8	54	94,7	84,66	15,73
Cycle 9 Day 1	n/a	43	29,3	21	48,8	83,17	15,29
Cycle 12 Day 1	n/a	41	27,9	23	56,1	83,19	16,80
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	78,39	21,44
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	87,78	10,53
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	83,81	17,82
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	86,38	19,74
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	86,39	15,91
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	84,35	17,71
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	86,39	16,97
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	89,20	12,81
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	88,48	14,13
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	87,78	15,04
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	85,24	17,96
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	83,89	17,86
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	83,67	13,74
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	85,33	12,82
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	83,33	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	86,67	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30PF.xls
18NOV2024 16:08

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Physical Functioning
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30PF.pdf
29JAN2025 17:35

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	56,26	23,58
Cycle 1 Day 8	n/a	139	94,6	132	95,0	57,01	22,18
Cycle 2 Day 1	n/a	122	83,0	114	93,4	60,53	21,24
Cycle 3 Day 1	n/a	104	70,7	93	89,4	63,35	21,71
Cycle 5 Day 1	n/a	80	54,4	73	91,3	65,07	19,53
Cycle 7 Day 1	n/a	57	38,8	53	93,0	66,67	21,56
Cycle 9 Day 1	n/a	43	29,3	21	48,8	71,03	21,18
Cycle 12 Day 1	n/a	41	27,9	23	56,1	67,03	27,69
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	59,01	23,89
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	74,65	20,04
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	66,96	24,37
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	67,39	25,49
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	68,40	25,18
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	66,30	22,96
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	61,46	23,93
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	70,29	23,81
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	70,83	21,32
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	67,59	20,79
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	60,12	20,72
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	69,44	24,45
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	70,00	16,76
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	60,00	21,57
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	83,33	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	50,00	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30QL.xls
18NOV2024 16:07

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Global Health Status
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30QL.pdf
29JAN2025 17:32

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	72,64	30,22
Cycle 1 Day 8	n/a	139	94,6	132	95,0	71,84	29,21
Cycle 2 Day 1	n/a	122	83,0	114	93,4	74,56	27,80
Cycle 3 Day 1	n/a	104	70,7	94	90,4	79,26	25,60
Cycle 5 Day 1	n/a	80	54,4	73	91,3	84,70	19,20
Cycle 7 Day 1	n/a	57	38,8	54	94,7	83,95	23,78
Cycle 9 Day 1	n/a	43	29,3	21	48,8	88,89	19,95
Cycle 12 Day 1	n/a	41	27,9	23	56,1	89,13	22,25
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	77,13	26,20
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	89,58	16,16
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	83,93	23,34
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	84,06	28,19
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	87,50	23,18
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	80,43	25,45
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	85,42	21,03
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	88,41	24,33
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	91,67	20,41
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	87,96	19,64
Follow up till Progression - 30 months	n/a	16	10,9	14	87,5	91,67	19,34
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	86,11	26,43
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	91,67	21,15
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	86,67	18,26
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	100,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	83,33	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30RF.xls
18NOV2024 16:11

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Role Functioning
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30RF.pdf
29JAN2025 17:38

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	145	98,6	76,09	27,27
Cycle 1 Day 8	n/a	139	94,6	132	95,0	77,90	25,18
Cycle 2 Day 1	n/a	122	83,0	114	93,4	79,53	26,89
Cycle 3 Day 1	n/a	104	70,7	94	90,4	81,56	23,63
Cycle 5 Day 1	n/a	80	54,4	73	91,3	84,93	21,00
Cycle 7 Day 1	n/a	57	38,8	54	94,7	84,57	24,41
Cycle 9 Day 1	n/a	43	29,3	21	48,8	86,51	18,72
Cycle 12 Day 1	n/a	41	27,9	23	56,1	85,51	24,26
Treatment Completion/ET Visit	n/a	129	87,8	86	66,7	79,46	26,16
Follow up till Progression - 3 months	n/a	37	25,2	24	64,9	90,97	17,71
Follow up till Progression - 6 months	n/a	37	25,2	28	75,7	95,83	14,07
Follow up till Progression - 9 months	n/a	35	23,8	23	65,7	82,61	32,36
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	90,97	19,02
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	90,58	21,22
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	91,67	16,30
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	94,20	17,12
Follow up till Progression - 24 months	n/a	23	15,6	22	95,7	94,70	15,76
Follow up till Progression - 27 months	n/a	19	12,9	18	94,7	91,67	18,30
Follow up till Progression - 30 months	n/a	16	10,9	15	93,8	90,00	19,72
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	84,72	29,69
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	91,67	16,20
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	86,67	18,26
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	83,33	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	100,00	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_C30SF.xls
18NOV2024 16:13

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: EORTC QLQ-C30: Scale Social Functioning
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_C30SF.pdf
29JAN2025 17:41

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: FACT-Lym Subscale Score (MID 9, worsening)
MODEL: --
STUDY: NP30179
Time to event analysis (efficacy)

		Glofitamab Cohorts D3 and D5 (N=148)											
		Patients		Patients with Event		Censored		Time To Event					
Name	Level	n	%	n	%	n	%	Q1 (months)	95% Lower CL for Q1	95% Upper CL for Q1	Median (months)	95% Lower CL for Median	95% Upper CL for Median
All	n/a	148	100,0	30	20,3	118	79,7	5,88	3,52	18,89	NE	18,53	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_tte_JUN24_ITT_D35_M9FLYM.xls
24MAR2025 21:54

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: FACT-Lym Subscale Score (MID 9, worsening)
MODEL: --
STUDY: NP30179
Kaplan-Meier plot of time to first event (months)



Patients at risk																	
Glofitamab Cohorts D3 and D5	148	71	38	32	29	25	24	22	21	19	19	15	13	9	8	5	NE
Patients censored																	
Glofitamab Cohorts D3 and D5	0	64	88	93	95	98	98	98	99	100	100	104	106	109	110	113	NE

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_tte.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_tte_JUN24_ITT_D35_M9FLYM.pdf
24MAR2025 22:08

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: FACT-Lym Subscale Score
MODEL: --
STUDY: NP30179
Compliance/Mean

		Glofitamab Cohorts D3 and D5 (N=148)					
		Patients				Statistics	
Name Visit	Level	in study[1]	%	with value[1]	%	mean[2]	SD
All							
BASELINE	n/a	147	100,0	138	93,9	14,76	9,09
Cycle 1 Day 8	n/a	139	94,6	131	94,2	13,54	8,77
Cycle 2 Day 1	n/a	122	83,0	113	92,6	12,31	8,76
Cycle 3 Day 1	n/a	104	70,7	93	89,4	10,83	7,80
Cycle 5 Day 1	n/a	80	54,4	74	92,5	10,18	8,05
Cycle 7 Day 1	n/a	57	38,8	52	91,2	10,07	7,85
Cycle 9 Day 1	n/a	43	29,3	20	46,5	8,41	8,15
Cycle 12 Day 1	n/a	41	27,9	22	53,7	10,35	10,01
Treatment Completion/ET Visit	n/a	129	87,8	84	65,1	12,36	8,69
Follow up till Progression - 3 months	n/a	37	25,2	23	62,2	9,27	6,67
Follow up till Progression - 6 months	n/a	37	25,2	26	70,3	8,48	6,65
Follow up till Progression - 9 months	n/a	35	23,8	21	60,0	10,02	9,45
Follow up till Progression - 12 months	n/a	31	21,1	24	77,4	8,97	8,45
Follow up till Progression - 15 months	n/a	30	20,4	23	76,7	9,35	9,33
Follow up till Progression - 18 months	n/a	27	18,4	24	88,9	10,28	8,92
Follow up till Progression - 21 months	n/a	25	17,0	23	92,0	7,56	9,48
Follow up till Progression - 24 months	n/a	23	15,6	23	100,0	8,56	8,03
Follow up till Progression - 27 months	n/a	19	12,9	17	89,5	9,70	10,25
Follow up till Progression - 30 months	n/a	16	10,9	15	93,8	9,96	11,16
Follow up till Progression - 33 months	n/a	15	10,2	12	80,0	8,55	10,41
Follow up till Progression - 36 months	n/a	10	6,8	10	100,0	5,50	3,41
Follow up till Progression - 39 months	n/a	5	3,4	5	100,0	8,00	4,30
Follow up till Progression - 42 months	n/a	2	1,4	1	50,0	9,00	NE
Follow up till Progression - 48 months	n/a	1	0,7	1	100,0	7,50	NE

[1] in study: number of subjects in study at respective visit; % based on baseline.
with value: number of subjects in study and with value at respective visit - used for the calculation of the mean and SD; % based on patients in study at respective visit.
[2] mean: descriptive statistics - absolute values
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_mean_JUN24_ITT_D35_FLYM.xls
18NOV2024 16:14

POPULATION: Cohorts D3 and D5 (R/R DLBCL Patients), Intent-to-Treat Patients
ENDPOINT: FACT-Lym Subscale Score
MODEL: --
STUDY: NP30179
Plot of Mean and 95% CI by Visit



Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/eff_g_mean.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/eff_g_mean_JUN24_ITT_D35_FLYM.pdf
29JAN2025 17:42

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: Any AEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	152	98,7	95,4	99,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AEANY.xls
18NOV2024 16:03

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AEs Grade >=3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	102	66,2	58,5	73,2

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AEGR345.xls
18NOV2024 16:04

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AEs Grade 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	62	40,3	32,8	48,2

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AEGR3.xls
18NOV2024 16:05

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AEs Grade 4
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	29	18,8	13,4	25,7

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AEGR4.xls
18NOV2024 16:06

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AEs Grade 5 (AEs leading to death)
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	11	7,1	4,0	12,3

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AEGR5.xls
18NOV2024 16:07

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: Any SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	76	49,4	41,6	57,2

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AESAE.xls
18NOV2024 16:08

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AEs leading to treatment discontinuation
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	14	9,1	5,5	14,7

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AEDISC.xls
18NOV2024 16:09

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: Any AEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

				Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	Blood and lymphatic system disorders	-Total	n/a	154	100,0	86	55,8	48,0	63,4
		Anaemia	n/a	154	100,0	46	29,9	23,2	37,5
		Anaemia of malignant disease	n/a	154	100,0	1	0,6	0,1	3,6
		Febrile neutropenia	n/a	154	100,0	4	2,6	1,0	6,5
		Hypofibrinogenaemia	n/a	154	100,0	1	0,6	0,1	3,6
		Iron deficiency anaemia	n/a	154	100,0	1	0,6	0,1	3,6
		Leukocytosis	n/a	154	100,0	1	0,6	0,1	3,6
		Lymphopenia	n/a	154	100,0	6	3,9	1,8	8,2
		Monocytosis	n/a	154	100,0	1	0,6	0,1	3,6
		Neutropenia	n/a	154	100,0	56	36,4	29,2	44,2
		Polycythaemia	n/a	154	100,0	1	0,6	0,1	3,6
		Thrombocytopenia	n/a	154	100,0	33	21,4	15,7	28,6
	Cardiac disorders	-Total	n/a	154	100,0	14	9,1	5,5	14,7
		Atrial fibrillation	n/a	154	100,0	3	1,9	0,7	5,6
		Cardiac failure	n/a	154	100,0	2	1,3	0,4	4,6
		Sinus bradycardia	n/a	154	100,0	1	0,6	0,1	3,6
		Sinus node dysfunction	n/a	154	100,0	1	0,6	0,1	3,6

		Sinus tachycardia	n/a	154	100,0	2	1,3	0,4	4,6
		Tachycardia	n/a	154	100,0	5	3,2	1,4	7,4
		Ventricular extrasystoles	n/a	154	100,0	1	0,6	0,1	3,6
	Ear and labyrinth disorders	-Total	n/a	154	100,0	4	2,6	1,0	6,5
		Ear congestion	n/a	154	100,0	1	0,6	0,1	3,6
		Ear pain	n/a	154	100,0	2	1,3	0,4	4,6
		Vertigo	n/a	154	100,0	2	1,3	0,4	4,6
	Endocrine disorders	-Total	n/a	154	100,0	1	0,6	0,1	3,6
		Hypothyroidism	n/a	154	100,0	1	0,6	0,1	3,6
	Eye disorders	-Total	n/a	154	100,0	6	3,9	1,8	8,2
		Conjunctival haemorrhage	n/a	154	100,0	1	0,6	0,1	3,6
		Conjunctivitis allergic	n/a	154	100,0	1	0,6	0,1	3,6
		Eye pain	n/a	154	100,0	2	1,3	0,4	4,6
		Periorbital pain	n/a	154	100,0	1	0,6	0,1	3,6
		Periorbital swelling	n/a	154	100,0	1	0,6	0,1	3,6
		Vision blurred	n/a	154	100,0	1	0,6	0,1	3,6
	Gastrointestinal disorders	-Total	n/a	154	100,0	73	47,4	39,7	55,3
		Abdominal discomfort	n/a	154	100,0	2	1,3	0,4	4,6
		Abdominal distension	n/a	154	100,0	2	1,3	0,4	4,6
		Abdominal pain	n/a	154	100,0	14	9,1	5,5	14,7
		Abdominal pain upper	n/a	154	100,0	3	1,9	0,7	5,6
		Anorectal discomfort	n/a	154	100,0	1	0,6	0,1	3,6
		Ascites	n/a	154	100,0	1	0,6	0,1	3,6
		Colitis	n/a	154	100,0	1	0,6	0,1	3,6

		Constipation	n/a	154	100,0	21	13,6	9,1	19,9
		Dental caries	n/a	154	100,0	1	0,6	0,1	3,6
		Diaphragmatic hernia	n/a	154	100,0	1	0,6	0,1	3,6
		Diarrhoea	n/a	154	100,0	20	13,0	8,6	19,2
		Dry mouth	n/a	154	100,0	1	0,6	0,1	3,6
		Duodenal obstruction	n/a	154	100,0	1	0,6	0,1	3,6
		Dyspepsia	n/a	154	100,0	1	0,6	0,1	3,6
		Dysphagia	n/a	154	100,0	1	0,6	0,1	3,6
		Faeces discoloured	n/a	154	100,0	1	0,6	0,1	3,6
		Gastric haemorrhage	n/a	154	100,0	1	0,6	0,1	3,6
		Gastric polyps	n/a	154	100,0	1	0,6	0,1	3,6
		Gastritis	n/a	154	100,0	2	1,3	0,4	4,6
		Gastrointestinal haemorrhage	n/a	154	100,0	2	1,3	0,4	4,6
		Haemorrhoids	n/a	154	100,0	1	0,6	0,1	3,6
		Intestinal perforation	n/a	154	100,0	1	0,6	0,1	3,6
		Large intestinal haemorrhage	n/a	154	100,0	1	0,6	0,1	3,6
		Nausea	n/a	154	100,0	16	10,4	6,5	16,2
		Stomatitis	n/a	154	100,0	2	1,3	0,4	4,6
		Toothache	n/a	154	100,0	4	2,6	1,0	6,5
		Umbilical hernia	n/a	154	100,0	1	0,6	0,1	3,6
		Vomiting	n/a	154	100,0	7	4,5	2,2	9,1
	General disorders and administration site conditions	-Total	n/a	154	100,0	65	42,2	34,7	50,1
		Asthenia	n/a	154	100,0	13	8,4	5,0	13,9

		Catheter site pain	n/a	154	100,0	1	0,6	0,1	3,6
		Catheter site pruritus	n/a	154	100,0	1	0,6	0,1	3,6
		Chest discomfort	n/a	154	100,0	1	0,6	0,1	3,6
		Chills	n/a	154	100,0	2	1,3	0,4	4,6
		Face oedema	n/a	154	100,0	1	0,6	0,1	3,6
		Facial pain	n/a	154	100,0	1	0,6	0,1	3,6
		Fatigue	n/a	154	100,0	17	11,0	7,0	17,0
		Gait disturbance	n/a	154	100,0	2	1,3	0,4	4,6
		General physical health deterioration	n/a	154	100,0	1	0,6	0,1	3,6
		Inflammation	n/a	154	100,0	1	0,6	0,1	3,6
		Injection site phlebitis	n/a	154	100,0	1	0,6	0,1	3,6
		Injection site reaction	n/a	154	100,0	1	0,6	0,1	3,6
		Localised oedema	n/a	154	100,0	1	0,6	0,1	3,6
		Malaise	n/a	154	100,0	3	1,9	0,7	5,6
		Oedema	n/a	154	100,0	4	2,6	1,0	6,5
		Oedema peripheral	n/a	154	100,0	9	5,8	3,1	10,7
		Pain	n/a	154	100,0	4	2,6	1,0	6,5
		Peripheral swelling	n/a	154	100,0	2	1,3	0,4	4,6
		Pyrexia	n/a	154	100,0	24	15,6	10,7	22,1
		Swelling	n/a	154	100,0	2	1,3	0,4	4,6
		Swelling face	n/a	154	100,0	2	1,3	0,4	4,6
	Hepatobiliary disorders	-Total	n/a	154	100,0	3	1,9	0,7	5,6
		Biliary colic	n/a	154	100,0	2	1,3	0,4	4,6

		Cholestasis	n/a	154	100,0	1	0,6	0,1	3,6
		Hepatic cytolysis	n/a	154	100,0	1	0,6	0,1	3,6
	Immune system disorders	-Total	n/a	154	100,0	105	68,2	60,5	75,0
		Cytokine release syndrome by ASTCT grade	n/a	154	100,0	103	66,9	59,1	73,8
		Cytokine release syndrome by Lee grade	n/a	154	100,0	103	66,9	59,1	73,8
		Hypogammaglobulinaemia	n/a	154	100,0	2	1,3	0,4	4,6
	Infections and infestations	-Total	n/a	154	100,0	64	41,6	34,1	49,5
		Abscess neck	n/a	154	100,0	1	0,6	0,1	3,6
		Appendicitis	n/a	154	100,0	1	0,6	0,1	3,6
		Bacterial infection	n/a	154	100,0	1	0,6	0,1	3,6
		Biliary tract infection bacterial	n/a	154	100,0	1	0,6	0,1	3,6
		Bronchitis	n/a	154	100,0	3	1,9	0,7	5,6
		COVID-19	n/a	154	100,0	10	6,5	3,6	11,5
		COVID-19 pneumonia	n/a	154	100,0	5	3,2	1,4	7,4
		Campylobacter infection	n/a	154	100,0	1	0,6	0,1	3,6
		Chronic sinusitis	n/a	154	100,0	1	0,6	0,1	3,6
		Clostridium difficile colitis	n/a	154	100,0	1	0,6	0,1	3,6
		Clostridium difficile infection	n/a	154	100,0	2	1,3	0,4	4,6
		Diverticulitis	n/a	154	100,0	1	0,6	0,1	3,6
		Escherichia infection	n/a	154	100,0	2	1,3	0,4	4,6
		Escherichia urinary tract infection	n/a	154	100,0	1	0,6	0,1	3,6

		Folliculitis	n/a	154	100,0	1	0,6	0,1	3,6
		Gastroenteritis	n/a	154	100,0	1	0,6	0,1	3,6
		Herpes zoster	n/a	154	100,0	3	1,9	0,7	5,6
		Infected skin ulcer	n/a	154	100,0	1	0,6	0,1	3,6
		Infection	n/a	154	100,0	2	1,3	0,4	4,6
		Influenza	n/a	154	100,0	1	0,6	0,1	3,6
		Klebsiella urinary tract infection	n/a	154	100,0	1	0,6	0,1	3,6
		Localised infection	n/a	154	100,0	1	0,6	0,1	3,6
		Muscle abscess	n/a	154	100,0	1	0,6	0,1	3,6
		Myelitis	n/a	154	100,0	1	0,6	0,1	3,6
		Nail infection	n/a	154	100,0	1	0,6	0,1	3,6
		Nasopharyngitis	n/a	154	100,0	2	1,3	0,4	4,6
		Neutropenic infection	n/a	154	100,0	1	0,6	0,1	3,6
		Oesophageal candidiasis	n/a	154	100,0	1	0,6	0,1	3,6
		Ophthalmic herpes zoster	n/a	154	100,0	1	0,6	0,1	3,6
		Oral candidiasis	n/a	154	100,0	1	0,6	0,1	3,6
		Paronychia	n/a	154	100,0	1	0,6	0,1	3,6
		Periodontitis	n/a	154	100,0	1	0,6	0,1	3,6
		Peritonitis	n/a	154	100,0	1	0,6	0,1	3,6
		Pneumococcal infection	n/a	154	100,0	1	0,6	0,1	3,6
		Pneumonia	n/a	154	100,0	8	5,2	2,7	9,9
		Respiratory tract infection	n/a	154	100,0	2	1,3	0,4	4,6
		Rhinitis	n/a	154	100,0	3	1,9	0,7	5,6

		Sepsis	n/a	154	100,0	6	3,9	1,8	8,2
		Sinusitis	n/a	154	100,0	3	1,9	0,7	5,6
		Skin infection	n/a	154	100,0	1	0,6	0,1	3,6
		Tooth abscess	n/a	154	100,0	1	0,6	0,1	3,6
		Tooth infection	n/a	154	100,0	2	1,3	0,4	4,6
		Upper respiratory tract infection	n/a	154	100,0	3	1,9	0,7	5,6
		Urinary tract infection	n/a	154	100,0	4	2,6	1,0	6,5
		Vascular device infection	n/a	154	100,0	3	1,9	0,7	5,6
		Viral upper respiratory tract infection	n/a	154	100,0	1	0,6	0,1	3,6
	Injury, poisoning and procedural complications	-Total	n/a	154	100,0	20	13,0	8,6	19,2
		Clavicle fracture	n/a	154	100,0	1	0,6	0,1	3,6
		Fall	n/a	154	100,0	3	1,9	0,7	5,6
		Humerus fracture	n/a	154	100,0	1	0,6	0,1	3,6
		Infusion related reaction	n/a	154	100,0	10	6,5	3,6	11,5
		Joint dislocation	n/a	154	100,0	1	0,6	0,1	3,6
		Muscle rupture	n/a	154	100,0	1	0,6	0,1	3,6
		Thermal burn	n/a	154	100,0	1	0,6	0,1	3,6
		Toxicity to various agents	n/a	154	100,0	1	0,6	0,1	3,6
		Wound complication	n/a	154	100,0	1	0,6	0,1	3,6
	Investigations	-Total	n/a	154	100,0	47	30,5	23,8	38,2
		Alanine aminotransferase increased	n/a	154	100,0	13	8,4	5,0	13,9

		Aspartate aminotransferase increased	n/a	154	100,0	12	7,8	4,5	13,1
		Blood alkaline phosphatase increased	n/a	154	100,0	13	8,4	5,0	13,9
		Blood bilirubin increased	n/a	154	100,0	6	3,9	1,8	8,2
		Blood creatinine increased	n/a	154	100,0	8	5,2	2,7	9,9
		Blood fibrinogen decreased	n/a	154	100,0	1	0,6	0,1	3,6
		Blood iron decreased	n/a	154	100,0	1	0,6	0,1	3,6
		Blood lactate dehydrogenase increased	n/a	154	100,0	3	1,9	0,7	5,6
		Blood lactic acid increased	n/a	154	100,0	1	0,6	0,1	3,6
		Blood urea increased	n/a	154	100,0	1	0,6	0,1	3,6
		Blood uric acid increased	n/a	154	100,0	1	0,6	0,1	3,6
		C-reactive protein increased	n/a	154	100,0	6	3,9	1,8	8,2
		Cardiac murmur	n/a	154	100,0	1	0,6	0,1	3,6
		Ejection fraction decreased	n/a	154	100,0	2	1,3	0,4	4,6
		Fibrin D dimer increased	n/a	154	100,0	2	1,3	0,4	4,6
		Gamma-glutamyltransferase increased	n/a	154	100,0	10	6,5	3,6	11,5
		Hepatic enzyme increased	n/a	154	100,0	2	1,3	0,4	4,6
		Liver function test abnormal	n/a	154	100,0	1	0,6	0,1	3,6

		Lymphocyte count decreased	n/a	154	100,0	1	0,6	0,1	3,6
		Neutrophil count decreased	n/a	154	100,0	3	1,9	0,7	5,6
		Neutrophil count increased	n/a	154	100,0	1	0,6	0,1	3,6
		Platelet count decreased	n/a	154	100,0	5	3,2	1,4	7,4
		Platelet count increased	n/a	154	100,0	1	0,6	0,1	3,6
		Polymerase chain reaction positive	n/a	154	100,0	2	1,3	0,4	4,6
		SARS-CoV-2 test positive	n/a	154	100,0	2	1,3	0,4	4,6
		Serum ferritin decreased	n/a	154	100,0	1	0,6	0,1	3,6
		Serum ferritin increased	n/a	154	100,0	2	1,3	0,4	4,6
		Troponin I increased	n/a	154	100,0	1	0,6	0,1	3,6
		Weight decreased	n/a	154	100,0	2	1,3	0,4	4,6
		White blood cell count decreased	n/a	154	100,0	3	1,9	0,7	5,6
		White blood cells urine positive	n/a	154	100,0	1	0,6	0,1	3,6
	Metabolism and nutrition disorders	-Total	n/a	154	100,0	68	44,2	36,6	52,0
		Decreased appetite	n/a	154	100,0	5	3,2	1,4	7,4
		Dehydration	n/a	154	100,0	2	1,3	0,4	4,6
		Fluid retention	n/a	154	100,0	1	0,6	0,1	3,6
		Hypercalcaemia	n/a	154	100,0	3	1,9	0,7	5,6
		Hyperglycaemia	n/a	154	100,0	4	2,6	1,0	6,5
		Hyperkalaemia	n/a	154	100,0	2	1,3	0,4	4,6

		Hyperlactacidaemia	n/a	154	100,0	1	0,6	0,1	3,6
		Hypermagnesaemia	n/a	154	100,0	2	1,3	0,4	4,6
		Hyperphosphataemia	n/a	154	100,0	3	1,9	0,7	5,6
		Hyperuricaemia	n/a	154	100,0	6	3,9	1,8	8,2
		Hypoalbuminaemia	n/a	154	100,0	2	1,3	0,4	4,6
		Hypocalcaemia	n/a	154	100,0	19	12,3	8,0	18,5
		Hypochloraemia	n/a	154	100,0	9	5,8	3,1	10,7
		Hypoglycaemia	n/a	154	100,0	1	0,6	0,1	3,6
		Hypokalaemia	n/a	154	100,0	17	11,0	7,0	17,0
		Hypomagnesaemia	n/a	154	100,0	22	14,3	9,6	20,7
		Hyponatraemia	n/a	154	100,0	11	7,1	4,0	12,3
		Hypophosphataemia	n/a	154	100,0	28	18,2	12,9	25,0
		Hypovolaemia	n/a	154	100,0	1	0,6	0,1	3,6
		Tumour lysis syndrome	n/a	154	100,0	3	1,9	0,7	5,6
	Musculoskeletal and connective tissue disorders	-Total	n/a	154	100,0	43	27,9	21,4	35,5
		Arthralgia	n/a	154	100,0	9	5,8	3,1	10,7
		Back pain	n/a	154	100,0	15	9,7	6,0	15,4
		Bone pain	n/a	154	100,0	3	1,9	0,7	5,6
		Bone swelling	n/a	154	100,0	1	0,6	0,1	3,6
		Flank pain	n/a	154	100,0	3	1,9	0,7	5,6
		Joint swelling	n/a	154	100,0	1	0,6	0,1	3,6
		Limb mass	n/a	154	100,0	1	0,6	0,1	3,6
		Muscle spasms	n/a	154	100,0	2	1,3	0,4	4,6
		Muscular weakness	n/a	154	100,0	3	1,9	0,7	5,6
		Musculoskeletal pain	n/a	154	100,0	1	0,6	0,1	3,6

		Myalgia	n/a	154	100,0	6	3,9	1,8	8,2
		Myofascial pain syndrome	n/a	154	100,0	1	0,6	0,1	3,6
		Neck pain	n/a	154	100,0	3	1,9	0,7	5,6
		Osteoarthritis	n/a	154	100,0	1	0,6	0,1	3,6
		Pain in extremity	n/a	154	100,0	4	2,6	1,0	6,5
		Pain in jaw	n/a	154	100,0	3	1,9	0,7	5,6
		Spinal osteoarthritis	n/a	154	100,0	1	0,6	0,1	3,6
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	154	100,0	29	18,8	13,4	25,7
		Acute myeloid leukaemia	n/a	154	100,0	1	0,6	0,1	3,6
		Adenocarcinoma pancreas	n/a	154	100,0	1	0,6	0,1	3,6
		Benign neoplasm of thyroid gland	n/a	154	100,0	1	0,6	0,1	3,6
		Melanoma recurrent	n/a	154	100,0	1	0,6	0,1	3,6
		Peripheral T-cell lymphoma unspecified	n/a	154	100,0	1	0,6	0,1	3,6
		Skin cancer	n/a	154	100,0	1	0,6	0,1	3,6
		Squamous cell carcinoma	n/a	154	100,0	1	0,6	0,1	3,6
		Transitional cell carcinoma	n/a	154	100,0	1	0,6	0,1	3,6
		Tumour associated fever	n/a	154	100,0	2	1,3	0,4	4,6
		Tumour flare	n/a	154	100,0	17	11,0	7,0	17,0
		Tumour pain	n/a	154	100,0	3	1,9	0,7	5,6
	Nervous system disorders	-Total	n/a	154	100,0	38	24,7	18,5	32,0
		Ageusia	n/a	154	100,0	1	0,6	0,1	3,6

		Cognitive disorder	n/a	154	100,0	1	0,6	0,1	3,6
		Dizziness	n/a	154	100,0	8	5,2	2,7	9,9
		Dysaesthesia	n/a	154	100,0	1	0,6	0,1	3,6
		Headache	n/a	154	100,0	15	9,7	6,0	15,4
		Hemiparaesthesia	n/a	154	100,0	1	0,6	0,1	3,6
		Myoclonus	n/a	154	100,0	1	0,6	0,1	3,6
		Neuropathy peripheral	n/a	154	100,0	3	1,9	0,7	5,6
		Paraesthesia	n/a	154	100,0	4	2,6	1,0	6,5
		Peripheral sensory neuropathy	n/a	154	100,0	2	1,3	0,4	4,6
		Presyncope	n/a	154	100,0	1	0,6	0,1	3,6
		Seizure	n/a	154	100,0	1	0,6	0,1	3,6
		Somnolence	n/a	154	100,0	2	1,3	0,4	4,6
		Transient ischaemic attack	n/a	154	100,0	1	0,6	0,1	3,6
		Tremor	n/a	154	100,0	2	1,3	0,4	4,6
	Psychiatric disorders	-Total	n/a	154	100,0	18	11,7	7,5	17,7
		Agitation	n/a	154	100,0	1	0,6	0,1	3,6
		Anxiety	n/a	154	100,0	6	3,9	1,8	8,2
		Confusional state	n/a	154	100,0	3	1,9	0,7	5,6
		Delirium	n/a	154	100,0	2	1,3	0,4	4,6
		Depression	n/a	154	100,0	1	0,6	0,1	3,6
		Disorientation	n/a	154	100,0	1	0,6	0,1	3,6
		Insomnia	n/a	154	100,0	3	1,9	0,7	5,6
		Mood altered	n/a	154	100,0	1	0,6	0,1	3,6
		Nervousness	n/a	154	100,0	1	0,6	0,1	3,6

	Renal and urinary disorders	-Total	n/a	154	100,0	9	5,8	3,1	10,7
		Acute kidney injury	n/a	154	100,0	2	1,3	0,4	4,6
		Cystitis noninfective	n/a	154	100,0	1	0,6	0,1	3,6
		Dysuria	n/a	154	100,0	2	1,3	0,4	4,6
		Hydronephrosis	n/a	154	100,0	1	0,6	0,1	3,6
		Nocturia	n/a	154	100,0	1	0,6	0,1	3,6
		Oliguria	n/a	154	100,0	2	1,3	0,4	4,6
		Pollakiuria	n/a	154	100,0	1	0,6	0,1	3,6
		Renal impairment	n/a	154	100,0	1	0,6	0,1	3,6
	Reproductive system and breast disorders	-Total	n/a	154	100,0	5	3,2	1,4	7,4
		Benign prostatic hyperplasia	n/a	154	100,0	1	0,6	0,1	3,6
		Erectile dysfunction	n/a	154	100,0	1	0,6	0,1	3,6
		Orchitis noninfective	n/a	154	100,0	1	0,6	0,1	3,6
		Prostatitis	n/a	154	100,0	2	1,3	0,4	4,6
	Respiratory, thoracic and mediastinal disorders	-Total	n/a	154	100,0	31	20,1	14,6	27,2
		Bronchopneumopathy	n/a	154	100,0	1	0,6	0,1	3,6
		Cough	n/a	154	100,0	8	5,2	2,7	9,9
		Cough variant asthma	n/a	154	100,0	1	0,6	0,1	3,6
		Dysphonia	n/a	154	100,0	2	1,3	0,4	4,6
		Dyspnoea	n/a	154	100,0	3	1,9	0,7	5,6
		Hiccups	n/a	154	100,0	1	0,6	0,1	3,6
		Hyperventilation	n/a	154	100,0	1	0,6	0,1	3,6
		Hypoxia	n/a	154	100,0	1	0,6	0,1	3,6
		Lung disorder	n/a	154	100,0	1	0,6	0,1	3,6

		Lung opacity	n/a	154	100,0	1	0,6	0,1	3,6
		Nasal congestion	n/a	154	100,0	1	0,6	0,1	3,6
		Oropharyngeal pain	n/a	154	100,0	2	1,3	0,4	4,6
		Orthopnoea	n/a	154	100,0	1	0,6	0,1	3,6
		Pleural effusion	n/a	154	100,0	4	2,6	1,0	6,5
		Pneumonitis	n/a	154	100,0	1	0,6	0,1	3,6
		Productive cough	n/a	154	100,0	2	1,3	0,4	4,6
		Pulmonary embolism	n/a	154	100,0	1	0,6	0,1	3,6
		Rales	n/a	154	100,0	1	0,6	0,1	3,6
		Rhinitis allergic	n/a	154	100,0	1	0,6	0,1	3,6
		Rhinorrhoea	n/a	154	100,0	2	1,3	0,4	4,6
		Sinus congestion	n/a	154	100,0	1	0,6	0,1	3,6
		Upper-airway cough syndrome	n/a	154	100,0	1	0,6	0,1	3,6
		Wheezing	n/a	154	100,0	1	0,6	0,1	3,6
	Skin and subcutaneous tissue disorders	-Total	n/a	154	100,0	36	23,4	17,4	30,7
		Actinic keratosis	n/a	154	100,0	1	0,6	0,1	3,6
		Dermatitis	n/a	154	100,0	1	0,6	0,1	3,6
		Dermatitis acneiform	n/a	154	100,0	1	0,6	0,1	3,6
		Dermatitis exfoliative	n/a	154	100,0	1	0,6	0,1	3,6
		Dry skin	n/a	154	100,0	1	0,6	0,1	3,6
		Eczema	n/a	154	100,0	2	1,3	0,4	4,6
		Erythema	n/a	154	100,0	8	5,2	2,7	9,9
		Hyperhidrosis	n/a	154	100,0	1	0,6	0,1	3,6

		Hyperkeratosis	n/a	154	100,0	1	0,6	0,1	3,6
		Night sweats	n/a	154	100,0	2	1,3	0,4	4,6
		Palmar erythema	n/a	154	100,0	1	0,6	0,1	3,6
		Pruritus	n/a	154	100,0	8	5,2	2,7	9,9
		Rash	n/a	154	100,0	9	5,8	3,1	10,7
		Rash erythematous	n/a	154	100,0	1	0,6	0,1	3,6
		Rash maculo-papular	n/a	154	100,0	4	2,6	1,0	6,5
		Rash pruritic	n/a	154	100,0	2	1,3	0,4	4,6
		Skin ulcer	n/a	154	100,0	1	0,6	0,1	3,6
		Urticaria	n/a	154	100,0	2	1,3	0,4	4,6
	Vascular disorders	-Total	n/a	154	100,0	15	9,7	6,0	15,4
		Embolism	n/a	154	100,0	1	0,6	0,1	3,6
		Hot flush	n/a	154	100,0	1	0,6	0,1	3,6
		Hypertension	n/a	154	100,0	3	1,9	0,7	5,6
		Hypotension	n/a	154	100,0	8	5,2	2,7	9,9
		Jugular vein thrombosis	n/a	154	100,0	1	0,6	0,1	3,6
		Phlebitis	n/a	154	100,0	2	1,3	0,4	4,6
		Phlebitis superficial	n/a	154	100,0	1	0,6	0,1	3,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_soc_JUN24_SE_D235_AEANY.xls
22JAN2025 12:28

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: Adverse Events Grade >=3 by Highest NCI CTCAE Grade (or Lee Grade for CRS events)
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)			
MedDRA System Organ Class MedDRA Preferred Term	Grade	n	%	95% CI (LL)(Wilson)	95% CI (UL)(Wilson)
- Any adverse events -	Grade 3-5	102	66,2	58,45	73,23
	3	62	40,3	32,84	48,15
	4	29	18,8	13,44	25,74
	5	11	7,1	4,03	12,34
Blood and lymphatic system disorders					
- Overall -	Grade 3-5	55	35,7	28,58	43,55
	3	35	22,7	16,82	29,96
	4	20	13,0	8,57	19,21
Anaemia	Grade 3-5	12	7,8	4,51	13,13
	3	12	7,8	4,51	13,13
Anaemia of malignant disease	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Febrile neutropenia	Grade 3-5	4	2,6	1,01	6,49
	3	2	1,3	0,36	4,61
	4	2	1,3	0,36	4,61
Hypofibrinogenaemia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Lymphopenia	Grade 3-5	6	3,9	1,8	8,24
	3	2	1,3	0,36	4,61
	4	4	2,6	1,01	6,49
Neutropenia	Grade 3-5	40	26,0	19,69	33,42
	3	27	17,5	12,34	24,31
	4	13	8,4	5	13,91
Thrombocytopenia	Grade 3-5	10	6,5	3,57	11,54
	3	8	5,2	2,66	9,92
	4	2	1,3	0,36	4,61

Cardiac disorders					
- Overall -	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Cardiac failure	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Eye disorders					
- Overall -	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Periorbital swelling	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Gastrointestinal disorders					
- Overall -	Grade 3-5	5	3,2	1,39	7,37
	3	2	1,3	0,36	4,61
	4	3	1,9	0,66	5,57
Ascites	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Colitis	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Duodenal obstruction	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Gastric haemorrhage	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Gastrointestinal haemorrhage	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Large intestinal haemorrhage	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
General disorders and administration site conditions					
- Overall -	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Asthenia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Fatigue	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59

General physical health deterioration	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pain	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Swelling	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Immune system disorders					
- Overall -	Grade 3-5	5	3,2	1,39	7,37
	3	3	1,9	0,66	5,57
	4	2	1,3	0,36	4,61
Cytokine release syndrome	Grade 3-5	5	3,2	1,39	7,37
	3	3	1,9	0,66	5,57
	4	2	1,3	0,36	4,61
Infections and infestations					
- Overall -	Grade 3-5	26	16,9	11,79	23,59
	3	12	7,8	4,51	13,13
	4	5	3,2	1,39	7,37
	5	9	5,8	3,1	10,73
Abscess neck	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Appendicitis	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Biliary tract infection bacterial	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
COVID-19	Grade 3-5	6	3,9	1,8	8,24
	3	2	1,3	0,36	4,61
	5	4	2,6	1,01	6,49
COVID-19 pneumonia	Grade 3-5	5	3,2	1,39	7,37
	3	2	1,3	0,36	4,61
	5	3	1,9	0,66	5,57
Clostridium difficile infection	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Gastroenteritis	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Influenza	Grade 3-5	1	0,6	0,11	3,59

	3	1	0,6	0,11	3,59
Myelitis	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Neutropenic infection	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Peritonitis	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pneumococcal infection	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pneumonia	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Sepsis	Grade 3-5	6	3,9	1,8	8,24
	3	1	0,6	0,11	3,59
	4	3	1,9	0,66	5,57
	5	2	1,3	0,36	4,61
Urinary tract infection	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Vascular device infection	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Injury, poisoning and procedural complications					
- Overall -	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Toxicity to various agents	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Investigations					
- Overall -	Grade 3-5	19	12,3	8,04	18,47
	3	13	8,4	5	13,91
	4	6	3,9	1,8	8,24
Alanine aminotransferase increased	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Aspartate aminotransferase increased	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49

Blood alkaline phosphatase increased	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Blood bilirubin increased	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
C-reactive protein increased	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Ejection fraction decreased	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Gamma-glutamyltransferase increased	Grade 3-5	4	2,6	1,01	6,49
	3	3	1,9	0,66	5,57
	4	1	0,6	0,11	3,59
Hepatic enzyme increased	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Lymphocyte count decreased	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Neutrophil count decreased	Grade 3-5	3	1,9	0,66	5,57
	3	1	0,6	0,11	3,59
	4	2	1,3	0,36	4,61
Platelet count decreased	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
SARS-CoV-2 test positive	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Weight decreased	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
White blood cell count decreased	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Metabolism and nutrition disorders					
- Overall -	Grade 3-5	18	11,7	7,52	17,72

	3	17	11,0	7,01	16,97
	4	1	0,6	0,11	3,59
Hypercalcaemia	Grade 3-5	3	1,9	0,66	5,57
	3	3	1,9	0,66	5,57
Hyperglycaemia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Hypoalbuminaemia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Hypokalaemia	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Hyponatraemia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Hypophosphataemia	Grade 3-5	9	5,8	3,1	10,73
	3	8	5,2	2,66	9,92
	4	1	0,6	0,11	3,59
Tumour lysis syndrome	Grade 3-5	3	1,9	0,66	5,57
	3	3	1,9	0,66	5,57
Musculoskeletal and connective tissue disorders					
- Overall -	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Back pain	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Pain in extremity	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pain in jaw	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Neoplasms benign, malignant and unspecified (incl cysts and polyps)					
- Overall -	Grade 3-5	9	5,8	3,1	10,73
	3	7	4,5	2,22	9,08
	4	1	0,6	0,11	3,59
	5	1	0,6	0,11	3,59
Acute myeloid leukaemia	Grade 3-5	1	0,6	0,11	3,59
	5	1	0,6	0,11	3,59
Adenocarcinoma pancreas	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59

Peripheral T-cell lymphoma unspecified	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Tumour flare	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Tumour pain	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Nervous system disorders					
- Overall -	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Somnolence	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Psychiatric disorders					
- Overall -	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	5	1	0,6	0,11	3,59
Delirium	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	5	1	0,6	0,11	3,59
Renal and urinary disorders					
- Overall -	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Acute kidney injury	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Oliguria	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Respiratory, thoracic and mediastinal disorders					
- Overall -	Grade 3-5	7	4,5	2,22	9,08
	3	7	4,5	2,22	9,08
Lung opacity	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pleural effusion	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Pulmonary embolism	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Wheezing	Grade 3-5	1	0,6	0,11	3,59

	3	1	0,6	0,11	3,59
Skin and subcutaneous tissue disorders					
- Overall -	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Rash	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Rash pruritic	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Vascular disorders					
- Overall -	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Hypertension	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59

Investigator text for AEs encoded using MedDRA version 27.0.
Only treatment emergent AEs are displayed. All counts represent numbers of Subjects. Multiple occurrences of the same preferred term in one individual are counted once at the highest grade for that preferred term. Adverse Events with missing CTC grades are excluded from this output.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/t_ae_ctc2.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/t_ae_ctc2_JUN24_SE_D235_AEGE3.xls
21MAR2025 16:06

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: Adverse Events Grade >=3 by Highest NCI CTCAE Grade (or ASTCT Grade for CRS events)
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)			
MedDRA System Organ Class MedDRA Preferred Term	Grade	n	%	95% CI (LL)(Wilson)	95% CI (UL)(Wilson)
- Any adverse events -	Grade 3-5	102	66,2	58,45	73,23
	3	62	40,3	32,84	48,15
	4	29	18,8	13,44	25,74
	5	11	7,1	4,03	12,34
Blood and lymphatic system disorders					
- Overall -	Grade 3-5	55	35,7	28,58	43,55
	3	35	22,7	16,82	29,96
	4	20	13,0	8,57	19,21
Anaemia	Grade 3-5	12	7,8	4,51	13,13
	3	12	7,8	4,51	13,13
Anaemia of malignant disease	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Febrile neutropenia	Grade 3-5	4	2,6	1,01	6,49
	3	2	1,3	0,36	4,61
	4	2	1,3	0,36	4,61
Hypofibrinogenaemia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Lymphopenia	Grade 3-5	6	3,9	1,8	8,24
	3	2	1,3	0,36	4,61
	4	4	2,6	1,01	6,49
Neutropenia	Grade 3-5	40	26,0	19,69	33,42
	3	27	17,5	12,34	24,31
	4	13	8,4	5	13,91
Thrombocytopenia	Grade 3-5	10	6,5	3,57	11,54
	3	8	5,2	2,66	9,92
	4	2	1,3	0,36	4,61
Cardiac disorders					
- Overall -	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61

Cardiac failure	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Eye disorders					
- Overall -	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Periorbital swelling	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Gastrointestinal disorders					
- Overall -	Grade 3-5	5	3,2	1,39	7,37
	3	2	1,3	0,36	4,61
	4	3	1,9	0,66	5,57
Ascites	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Colitis	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Duodenal obstruction	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Gastric haemorrhage	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Gastrointestinal haemorrhage	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Large intestinal haemorrhage	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
General disorders and administration site conditions					
- Overall -	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Asthenia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Fatigue	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
General physical health deterioration	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pain	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Swelling	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59

Immune system disorders					
- Overall -	Grade 3-5	6	3,9	1,8	8,24
	3	4	2,6	1,01	6,49
	4	2	1,3	0,36	4,61
Cytokine release syndrome	Grade 3-5	6	3,9	1,8	8,24
	3	4	2,6	1,01	6,49
	4	2	1,3	0,36	4,61
Infections and infestations					
- Overall -	Grade 3-5	26	16,9	11,79	23,59
	3	12	7,8	4,51	13,13
	4	5	3,2	1,39	7,37
	5	9	5,8	3,1	10,73
Abscess neck	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Appendicitis	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Biliary tract infection bacterial	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
COVID-19	Grade 3-5	6	3,9	1,8	8,24
	3	2	1,3	0,36	4,61
	5	4	2,6	1,01	6,49
COVID-19 pneumonia	Grade 3-5	5	3,2	1,39	7,37
	3	2	1,3	0,36	4,61
	5	3	1,9	0,66	5,57
Clostridium difficile infection	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Gastroenteritis	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Influenza	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Myelitis	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Neutropenic infection	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Peritonitis	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pneumococcal infection	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pneumonia	Grade 3-5	2	1,3	0,36	4,61

	3	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Sepsis	Grade 3-5	6	3,9	1,8	8,24
	3	1	0,6	0,11	3,59
	4	3	1,9	0,66	5,57
	5	2	1,3	0,36	4,61
Urinary tract infection	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Vascular device infection	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Injury, poisoning and procedural complications					
- Overall -	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Toxicity to various agents	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Investigations					
- Overall -	Grade 3-5	19	12,3	8,04	18,47
	3	13	8,4	5	13,91
	4	6	3,9	1,8	8,24
Alanine aminotransferase increased	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Aspartate aminotransferase increased	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Blood alkaline phosphatase increased	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Blood bilirubin increased	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
C-reactive protein increased	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Ejection fraction decreased	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Gamma-glutamyltransferase increased	Grade 3-5	4	2,6	1,01	6,49

	3	3	1,9	0,66	5,57
	4	1	0,6	0,11	3,59
Hepatic enzyme increased	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Lymphocyte count decreased	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Neutrophil count decreased	Grade 3-5	3	1,9	0,66	5,57
	3	1	0,6	0,11	3,59
	4	2	1,3	0,36	4,61
Platelet count decreased	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
SARS-CoV-2 test positive	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Weight decreased	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
White blood cell count decreased	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Metabolism and nutrition disorders					
- Overall -	Grade 3-5	18	11,7	7,52	17,72
	3	17	11,0	7,01	16,97
	4	1	0,6	0,11	3,59
Hypercalcaemia	Grade 3-5	3	1,9	0,66	5,57
	3	3	1,9	0,66	5,57
Hyperglycaemia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Hypoalbuminaemia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Hypokalaemia	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Hyponatraemia	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Hypophosphataemia	Grade 3-5	9	5,8	3,1	10,73
	3	8	5,2	2,66	9,92
	4	1	0,6	0,11	3,59
Tumour lysis syndrome	Grade 3-5	3	1,9	0,66	5,57
	3	3	1,9	0,66	5,57

Musculoskeletal and connective tissue disorders					
- Overall -	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Back pain	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Pain in extremity	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pain in jaw	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Neoplasms benign, malignant and unspecified (incl cysts and polyps)					
- Overall -	Grade 3-5	9	5,8	3,1	10,73
	3	7	4,5	2,22	9,08
	4	1	0,6	0,11	3,59
	5	1	0,6	0,11	3,59
Acute myeloid leukaemia	Grade 3-5	1	0,6	0,11	3,59
	5	1	0,6	0,11	3,59
Adenocarcinoma pancreas	Grade 3-5	1	0,6	0,11	3,59
	4	1	0,6	0,11	3,59
Peripheral T-cell lymphoma unspecified	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Tumour flare	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Tumour pain	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Nervous system disorders					
- Overall -	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Somnolence	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Psychiatric disorders					
- Overall -	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	5	1	0,6	0,11	3,59
Delirium	Grade 3-5	2	1,3	0,36	4,61
	3	1	0,6	0,11	3,59
	5	1	0,6	0,11	3,59

Renal and urinary disorders					
- Overall -	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Acute kidney injury	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Oliguria	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Respiratory, thoracic and mediastinal disorders					
- Overall -	Grade 3-5	7	4,5	2,22	9,08
	3	7	4,5	2,22	9,08
Lung opacity	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Pleural effusion	Grade 3-5	4	2,6	1,01	6,49
	3	4	2,6	1,01	6,49
Pulmonary embolism	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Wheezing	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Skin and subcutaneous tissue disorders					
- Overall -	Grade 3-5	2	1,3	0,36	4,61
	3	2	1,3	0,36	4,61
Rash	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Rash pruritic	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Vascular disorders					
- Overall -	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59
Hypertension	Grade 3-5	1	0,6	0,11	3,59
	3	1	0,6	0,11	3,59

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/t_ae_ctc3.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/t_ae_ctc3_JUN24_SE_D235_ASTCGE3.xls
21MAR2025 15:56

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: Any SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

				Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
				Patients		Patients with Event			
Name	SOC	PT	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	Blood and lymphatic system disorders	-Total	n/a	154	100,0	10	6,5	3,6	11,5
		Anaemia	n/a	154	100,0	3	1,9	0,7	5,6
		Febrile neutropenia	n/a	154	100,0	3	1,9	0,7	5,6
		Lymphopenia	n/a	154	100,0	1	0,6	0,1	3,6
		Neutropenia	n/a	154	100,0	3	1,9	0,7	5,6
		Thrombocytopenia	n/a	154	100,0	1	0,6	0,1	3,6
	Cardiac disorders	-Total	n/a	154	100,0	2	1,3	0,4	4,6
		Cardiac failure	n/a	154	100,0	1	0,6	0,1	3,6
		Sinus node dysfunction	n/a	154	100,0	1	0,6	0,1	3,6
	Eye disorders	-Total	n/a	154	100,0	1	0,6	0,1	3,6
		Vision blurred	n/a	154	100,0	1	0,6	0,1	3,6
	Gastrointestinal disorders	-Total	n/a	154	100,0	7	4,5	2,2	9,1
		Colitis	n/a	154	100,0	1	0,6	0,1	3,6
		Constipation	n/a	154	100,0	1	0,6	0,1	3,6
		Duodenal obstruction	n/a	154	100,0	1	0,6	0,1	3,6
		Gastric haemorrhage	n/a	154	100,0	1	0,6	0,1	3,6
		Gastrointestinal haemorrhage	n/a	154	100,0	2	1,3	0,4	4,6

		Intestinal perforation	n/a	154	100,0	1	0,6	0,1	3,6
		Large intestinal haemorrhage	n/a	154	100,0	1	0,6	0,1	3,6
		Nausea	n/a	154	100,0	1	0,6	0,1	3,6
		Vomiting	n/a	154	100,0	1	0,6	0,1	3,6
	General disorders and administration site conditions	-Total	n/a	154	100,0	4	2,6	1,0	6,5
		Asthenia	n/a	154	100,0	1	0,6	0,1	3,6
		Gait disturbance	n/a	154	100,0	1	0,6	0,1	3,6
		General physical health deterioration	n/a	154	100,0	1	0,6	0,1	3,6
		Pyrexia	n/a	154	100,0	2	1,3	0,4	4,6
	Immune system disorders	-Total	n/a	154	100,0	34	22,1	16,3	29,3
		Cytokine release syndrome by ASTCT grade	n/a	154	100,0	34	22,1	16,3	29,3
		Cytokine release syndrome by Lee grade	n/a	154	100,0	34	22,1	16,3	29,3
	Infections and infestations	-Total	n/a	154	100,0	28	18,2	12,9	25,0
		Abscess neck	n/a	154	100,0	1	0,6	0,1	3,6
		Appendicitis	n/a	154	100,0	1	0,6	0,1	3,6
		Biliary tract infection bacterial	n/a	154	100,0	1	0,6	0,1	3,6
		COVID-19	n/a	154	100,0	5	3,2	1,4	7,4
		COVID-19 pneumonia	n/a	154	100,0	5	3,2	1,4	7,4
		Campylobacter infection	n/a	154	100,0	1	0,6	0,1	3,6
		Clostridium difficile colitis	n/a	154	100,0	1	0,6	0,1	3,6
		Infection	n/a	154	100,0	2	1,3	0,4	4,6

		Muscle abscess	n/a	154	100,0	1	0,6	0,1	3,6
		Myelitis	n/a	154	100,0	1	0,6	0,1	3,6
		Neutropenic infection	n/a	154	100,0	1	0,6	0,1	3,6
		Peritonitis	n/a	154	100,0	1	0,6	0,1	3,6
		Pneumococcal infection	n/a	154	100,0	1	0,6	0,1	3,6
		Pneumonia	n/a	154	100,0	2	1,3	0,4	4,6
		Sepsis	n/a	154	100,0	6	3,9	1,8	8,2
		Urinary tract infection	n/a	154	100,0	1	0,6	0,1	3,6
		Vascular device infection	n/a	154	100,0	2	1,3	0,4	4,6
	Injury, poisoning and procedural complications	-Total	n/a	154	100,0	3	1,9	0,7	5,6
		Infusion related reaction	n/a	154	100,0	1	0,6	0,1	3,6
		Joint dislocation	n/a	154	100,0	1	0,6	0,1	3,6
		Toxicity to various agents	n/a	154	100,0	1	0,6	0,1	3,6
	Investigations	-Total	n/a	154	100,0	2	1,3	0,4	4,6
		C-reactive protein increased	n/a	154	100,0	1	0,6	0,1	3,6
		Weight decreased	n/a	154	100,0	1	0,6	0,1	3,6
	Musculoskeletal and connective tissue disorders	-Total	n/a	154	100,0	2	1,3	0,4	4,6
		Back pain	n/a	154	100,0	2	1,3	0,4	4,6
	Neoplasms benign, malignant and unspecified (incl cysts and polyps)	-Total	n/a	154	100,0	10	6,5	3,6	11,5
		Acute myeloid leukaemia	n/a	154	100,0	1	0,6	0,1	3,6
		Adenocarcinoma pancreas	n/a	154	100,0	1	0,6	0,1	3,6

		Transitional cell carcinoma	n/a	154	100,0	1	0,6	0,1	3,6
		Tumour associated fever	n/a	154	100,0	1	0,6	0,1	3,6
		Tumour flare	n/a	154	100,0	5	3,2	1,4	7,4
		Tumour pain	n/a	154	100,0	1	0,6	0,1	3,6
	Nervous system disorders	-Total	n/a	154	100,0	2	1,3	0,4	4,6
		Dizziness	n/a	154	100,0	1	0,6	0,1	3,6
		Transient ischaemic attack	n/a	154	100,0	1	0,6	0,1	3,6
	Psychiatric disorders	-Total	n/a	154	100,0	2	1,3	0,4	4,6
		Delirium	n/a	154	100,0	2	1,3	0,4	4,6
	Renal and urinary disorders	-Total	n/a	154	100,0	2	1,3	0,4	4,6
		Acute kidney injury	n/a	154	100,0	2	1,3	0,4	4,6
	Respiratory, thoracic and mediastinal disorders	-Total	n/a	154	100,0	4	2,6	1,0	6,5
		Pleural effusion	n/a	154	100,0	3	1,9	0,7	5,6
		Pulmonary embolism	n/a	154	100,0	1	0,6	0,1	3,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw_soc.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_soc_JUN24_SE_D235_AESAE.xls
22JAN2025 12:33

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AEs leading to treatment discontinuation
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

			Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)			
			Patients		Patients with Event	
MedDRA System Organ Class	MedDRA Preferred Term	Level	n	%	n	%
Blood and lymphatic system disorders		n/a	154	100,0	2	1,3
Blood and lymphatic system disorders	Neutropenia	n/a	154	100,0	2	1,3
Gastrointestinal disorders		n/a	154	100,0	1	0,6
Gastrointestinal disorders	Gastrointestinal haemorrhage	n/a	154	100,0	1	0,6
Hepatobiliary disorders		n/a	154	100,0	1	0,6
Hepatobiliary disorders	Cholestasis	n/a	154	100,0	1	0,6
Hepatobiliary disorders	Hepatic cytolysis	n/a	154	100,0	1	0,6
Immune system disorders		n/a	154	100,0	1	0,6
Immune system disorders	Cytokine release syndrome by ASTCT grade	n/a	154	100,0	1	0,6
Immune system disorders	Cytokine release syndrome by Lee grade	n/a	154	100,0	1	0,6
Infections and infestations		n/a	154	100,0	6	3,9
Infections and infestations	Biliary tract infection bacterial	n/a	154	100,0	1	0,6
Infections and infestations	COVID-19	n/a	154	100,0	2	1,3
Infections and infestations	COVID-19 pneumonia	n/a	154	100,0	1	0,6
Infections and infestations	Myelitis	n/a	154	100,0	1	0,6
Infections and infestations	Sepsis	n/a	154	100,0	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)		n/a	154	100,0	1	0,6
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	Melanoma recurrent	n/a	154	100,0	1	0,6
Psychiatric disorders		n/a	154	100,0	2	1,3
Psychiatric disorders	Delirium	n/a	154	100,0	2	1,3

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/t_ae_socdesc.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/t_ae_socdesc_JUN24_SE_D235_AEDISC.xls
27MAR2025 18:24

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: AST, ALT, or total bilirubin elevation - Grade >= 2
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	12	7,8	4,5	13,1

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ABIL.xls
22JAN2025 13:04

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Colitis
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	1	0,6	0,1	3,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACOL.xls
22JAN2025 13:15

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - Grade >= 2
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	25	16,2	11,2	22,9

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACRS.xls
22JAN2025 12:44

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by Lee grade - Grade >= 2
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	29	18,8	13,4	25,7

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACRSL.xls
22JAN2025 12:47

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Disseminated Intravascular Coagulation - Grade >= 2
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ADIC.xls
22JAN2025 13:07

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Drug-induced liver injury (DILI) adverse events
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ADILI.xls
22JAN2025 12:39

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Febrile Neutropenia - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	4	2,6	1,0	6,5

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AFEB.xls
22JAN2025 13:01

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Hemophagocytic lymphohistiocytosis
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AHEMA.xls
22JAN2025 12:55

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Secondary malignancies
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	4	2,6	1,0	6,5

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AMAL.xls
22JAN2025 13:18

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Neurologic AEs - Grade >= 2
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	27	17,5	12,3	24,3

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ANAE.xls
22JAN2025 12:51

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Pneumonitis or interstitial lung disease
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	2	1,3	0,4	4,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_APILD.xls
22JAN2025 13:12

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse events
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ASTIAMP.xls
22JAN2025 12:41

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Tumor flare - Grade >= 2
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	11	7,1	4,0	12,3

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ATF.xls
22JAN2025 13:09

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Tumor lysis syndrome - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	3	1,9	0,7	5,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ATLS.xls
22JAN2025 12:57

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: AST, ALT, or total bilirubin elevation - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	6	3,9	1,8	8,2

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ABIL345.xls
22JAN2025 13:05

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Colitis - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	1	0,6	0,1	3,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACOL345.xls
22JAN2025 13:16

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	6	3,9	1,8	8,2

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACRS345.xls
22JAN2025 12:45

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by Lee grade - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	5	3,2	1,4	7,4

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACRSL345.xls
22JAN2025 12:49

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Disseminated Intravascular Coagulation - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ADIC345.xls
22JAN2025 13:07

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Drug-induced liver injury (DILI) adverse events - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ADILI345.xls
22JAN2025 12:40

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Febrile Neutropenia - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	4	2,6	1,0	6,5

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AFEB345.xls
22JAN2025 13:02

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Hemophagocytic lymphohistiocytosis - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AHEMA345.xls
22JAN2025 12:56

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Secondary malignancies - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	3	1,9	0,7	5,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AMAL345.xls
22JAN2025 13:19

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Neurologic AEs - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	5	3,2	1,4	7,4

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ANAE345.xls
22JAN2025 12:53

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Pneumonitis or interstitial lung disease - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	1	0,6	0,1	3,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_APILD345.xls
22JAN2025 13:13

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse events - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ASTIA345.xls
22JAN2025 12:42

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Tumor flare - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	4	2,6	1,0	6,5

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ATF345.xls
22JAN2025 13:10

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Tumor lysis syndrome - Grade >= 3
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	3	1,9	0,7	5,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ATLS345.xls
22JAN2025 12:59

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: AST, ALT, or total bilirubin elevation - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ABILSAE.xls
22JAN2025 13:06

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Colitis - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	1	0,6	0,1	3,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACOLSAE.xls
22JAN2025 13:17

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by Lee grade - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	18	11,7	7,5	17,7

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACRSLSAE.xls
22JAN2025 12:50

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Cytokine release syndrome by ASTCT grade - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	16	10,4	6,5	16,2

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ACRSSAE.xls
22JAN2025 12:46

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Disseminated Intravascular Coagulation - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ADICSAE.xls
22JAN2025 13:08

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Drug-induced liver injury (DILI) - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ADILISAE.xls
22JAN2025 12:41

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Febrile Neutropenia - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	3	1,9	0,7	5,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AFEBSAE.xls
22JAN2025 13:03

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Hemophagocytic lymphohistiocytosis - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AHEMASAE.xls
22JAN2025 12:56

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Secondary malignancies - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	2	1,3	0,4	4,6

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_AMALSAE.xls
22JAN2025 13:20

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Neurologic AEs - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	4	2,6	1,0	6,5

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ANAESAE.xls
22JAN2025 12:54

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Pneumonitis or interstitial lung disease - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_APILDSAE.xls
22JAN2025 13:14

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Suspected transmission of an infectious agent by the study treatment (STIAMP) - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ASTIASAE.xls
22JAN2025 12:43

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Tumor flare - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)					
		Patients		Patients with Event			
Name	Level	n	%	n	%	95% CI (LL)	95% CI (UL)
All	n/a	154	100,0	4	2,6	1,0	6,5

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ATFSAE.xls
22JAN2025 13:11

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: AESI: Tumor lysis syndrome - SAEs
MODEL: --
STUDY: NP30179
Dichotomous analysis (safety)

Null Report: No observations met the reporting criteria for inclusion in this output.

95% CI based on Wilson Scores.
Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_raw.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_raw_JUN24_SE_D235_ATLSSAE.xls
22JAN2025 13:00

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Outcome of Adverse Events

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)															
		Total		RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING	
Category of Adverse Events		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
Any AEs																	
	All	1365	100,0	1025	75,1	4	0,3	309	22,6	11	0,8	15	1,1	0	0,0	1	<0.1
	Grade 1	762	100,0	599	78,6	1	0,1	152	19,9	0	0,0	10	1,3	0	0,0	0	0,0
	Grade 2	366	100,0	256	69,9	3	0,8	102	27,9	0	0,0	4	1,1	0	0,0	1	0,3
	Grade 3	183	100,0	138	75,4	0	0,0	45	24,6	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	43	100,0	32	74,4	0	0,0	10	23,3	0	0,0	1	2,3	0	0,0	0	0,0
	Grade 5	11	100,0	0	0,0	0	0,0	0	0,0	11	100,0	0	0,0	0	0,0	0	0,0
	Missing	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Any SAEs																	
	All	139	100,0	109	78,4	0	0,0	18	12,9	11	7,9	1	0,7	0	0,0	0	0,0
	Grade 1	34	100,0	31	91,2	0	0,0	3	8,8	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	32	100,0	30	93,8	0	0,0	2	6,3	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	43	100,0	35	81,4	0	0,0	8	18,6	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	19	100,0	13	68,4	0	0,0	5	26,3	0	0,0	1	5,3	0	0,0	0	0,0
	Grade 5	11	100,0	0	0,0	0	0,0	0	0,0	11	100,0	0	0,0	0	0,0	0	0,0
	Missing	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
Any AESI																	
	All	111	100,0	77	69,4	1	0,9	29	26,1	2	1,8	2	1,8	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	72	100,0	51	70,8	1	1,4	19	26,4	0	0,0	1	1,4	0	0,0	0	0,0
	Grade 3	30	100,0	22	73,3	0	0,0	8	26,7	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	7	100,0	4	57,1	0	0,0	2	28,6	0	0,0	1	14,3	0	0,0	0	0,0
	Grade 5	2	100,0	0	0,0	0	0,0	0	0,0	2	100,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0

Clinical cut-off: 17MAY2024

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_resolved.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_resolved_JUN24_SE_D235.xls
27MAR2025 10:43

POPULATION: Cohorts D2 (Sub 2), D3, D5 (R/R DLBCL Patients), Safety-Evaluable Patients
ENDPOINT: All patients
MODEL: --
STUDY: NP30179
Outcome of Adverse Events

		Glofitamab Cohorts D2 (Sub 2), D3, D5 (N=154)															
		Total		RECOVERED/RESOLVED		RECOVERED/RESOLVED WITH SEQUELAE		NOT RECOVERED/NOT RESOLVED		FATAL		RECOVERING/RESOLVING		UNKNOWN		MISSING	
Category of Adverse Events		n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
AESI: Cytokine release syndrome by Lee grade, Grade >= 2																	
	All	33	100,0	31	93,9	0	0,0	2	6,1	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	28	100,0	27	96,4	0	0,0	1	3,6	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	4	100,0	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	2	100,0	1	50,0	0	0,0	1	50,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Cytokine release syndrome by Lee grade, Grade >= 2																	
	All	18	100,0	17	94,4	0	0,0	1	5,6	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	13	100,0	13	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	4	100,0	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	2	100,0	1	50,0	0	0,0	1	50,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Cytokine release syndrome by ASTCT grade, Grade >= 2																	
	All	27	100,0	26	96,3	0	0,0	1	3,7	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	21	100,0	21	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	4	100,0	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	2	100,0	1	50,0	0	0,0	1	50,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Cytokine release syndrome by ASTCT grade, Grade >= 2																	
	All	16	100,0	15	93,8	0	0,0	1	6,3	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	10	100,0	10	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	4	100,0	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	2	100,0	1	50,0	0	0,0	1	50,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Neurologic AEs, Grade >= 2																	
	All	30	100,0	13	43,3	1	3,3	14	46,7	1	3,3	1	3,3	0	0,0	0	0,0
	Grade 2	25	100,0	13	52,0	1	4,0	10	40,0	0	0,0	1	4,0	0	0,0	0	0,0
	Grade 3	3	100,0	0	0,0	0	0,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	1	100,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	1	100,0	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0

AESI: Serious Neurologic AEs, Grade >= 2																	
	All	4	100,0	1	25,0	0	0,0	2	50,0	1	25,0	0	0,0	0	0,0	0	0,0
	Grade 2	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	1	100,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	1	100,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	1	100,0	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Any suspected HLH																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Any suspected HLH																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Tumor lysis syndrome, Grade >= 3																	
	All	3	100,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	3	100,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Tumor lysis syndrome, Grade >= 3																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Febrile Neutropenia, Grade >= 3																	
	All	6	100,0	6	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	4	100,0	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	2	100,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Febrile Neutropenia, Grade >= 3																	
	All	5	100,0	5	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	3	100,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	2	100,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0

AESI: AST, ALT, or total bilirubin elevation, Grade >= 2																	
	All	20	100,0	10	50,0	0	0,0	10	50,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	9	100,0	3	33,3	0	0,0	6	66,7	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	11	100,0	7	63,6	0	0,0	4	36,4	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious AST, ALT, or total bilirubin elevation, Grade >= 2																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Disseminated Intravascular Coagulation, Grade >= 2																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Disseminated Intravascular Coagulation, Grade >= 2																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Tumour flare, Grade >= 2																	
	All	11	100,0	10	90,9	0	0,0	1	9,1	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	7	100,0	6	85,7	0	0,0	1	14,3	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	4	100,0	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Tumour flare, Grade >= 2																	
	All	4	100,0	4	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	3	100,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Pneumonitis or interstitial lung disease																	
	All	2	100,0	2	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0

	Grade 2	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Pneumonitis or interstitial lung disease																	
	All	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Colitis																	
	All	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Colitis																	
	All	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Obinutuzumab - Secondary malignancies																	
	All	5	100,0	2	40,0	0	0,0	2	40,0	1	20,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	2	100,0	1	50,0	0	0,0	1	50,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	1	100,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	1	100,0	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Obinutuzumab - Secondary malignancies																	
	All	2	100,0	1	50,0	0	0,0	0	0,0	1	50,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	1	100,0	1	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	1	100,0	0	0,0	0	0,0	0	0,0	1	100,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Obinutuzumab - TLS																	
	All	3	100,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	3	100,0	3	100,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0

	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Obinutuzumab - TLS																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Drug-induced liver injury (DILI) adverse event																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Drug-induced liver injury (DILI) adverse event																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
AESI: Serious Suspected transmission of an infectious agent by the study treatment (STIAMP) adverse event																	
	All	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 1	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 2	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 3	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 4	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Grade 5	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0
	Missing	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0	0	0,0

Program: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_BASE/prod/program/saf_resolved_aesi.sas
Output: root/clinical_studies/RO7082859/CDT70029/NP30179/data_analysis/ACE_CSRUpdate_2yr_Jun2024/prod/output/saf_resolved_aesi_JUN24_SE_D235.xls
27MAR2025 10:45